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Abstract 
 
Targeted delivery is an important area of biomedical research, which can reduce side effects in 
clinical field. Various carriers, such as organic, inorganic particles, liposome, polymer, etc., have been 
utilized in targeted delivery. However, these vehicles have several difficulties such as the complexity 
of synthesis, heterogeneous size and shape and lower biocompatibility. Protein nanoparticles could be 
an attractive candidate as delivery vehicles. Protein nanoparticles have well-defined structure with 
high symmetry, uniform size and shape. These particles have also biodegradability, greater stability 
during in vivo circulation and being easy to prepare the particles. And protein nanoparticles can attach 
drugs, fluorescent dye, enzymes, radioactive isotopes, antigens, or antibodies at desired site depending 
on their purpose.  
In this study, we used Aquifex aeolicus Lumazine synthase (AaLS) as a targeted delivery vehicle. 
Antibody binding domain (ABD), which was known to selectively bind to Fc part of the antibody, 
was genetically encoded to AaLS (ABD-AaLS). We have designed a modular delivery platform that 
can deliver drugs to a variety of cancer cells by binding various antibodies to ABD. This platform can 
deliver drug to variety of target cancer cells in in vitro.  
Recently we have developed a targeted delivery platform using P22 virus-like particle (P22 VLP) 
that is relatively large-sized protein cage nanoparticles. We covalently attached affibody to exterior 
surface of P22 VLP using bacterial superglue system. These platforms successfully delivered 
anticancer drug, doxorubicin, to tumor site and showed tumor specific killing effect.  
In addition, we developed the cloaking drug delivery system using mesoporous silica nanoparticles 
(MSNs). We constructed GST fused affibody molecules and bound these fusion proteins on MSNs as 
capping materials. This pre-coated nanoparticles blocked nonspecific binding of serum proteins, 
avoiding immune response, while maintaining targeting ability in vivo. 
Our studies demonstrated that protein nanoparticles are promising platforms for diagnostic and/or 
therapeutic agent delivery in biomedical field. 
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Chapter 1. Introduction 
 
 
1.1 Nanoparticle-based cargo delivery 
Nanomedicine is the biomedical application using nanotechnology. Nanomedicine is a  
large category including application of nanomaterials and nanodevice for drug delivery, 
diagnosis, biosensing, and tissue engineering. The nanomedicine has similar size and 
structure to biological molecules, therefore the nanomaterials are promising platform. Among 
the various nanomedicine area, nano based drug delivery system is the most actively studied 
field (Figure 1.1)1. Encapsulating therapeutic drugs in nanomaterials and delivering these 
carriers to target tissues still remain major task of therapeutics. To develop ideal 
nanomedicine avoiding side effect, we have to understand in detail the types and properties of 
nanoparticles. 
 
1.1.1 Characteristics of nanoparticles as delivery carrier 
Conventional drugs and diagnostic probes have a few limitations for biomedical 
application. Drugs and diagnostic probes rapidly diffuse and spread throughout the body, 
which cause adverse effects in normal cells and tissues. Some cargoes, such as protein 
and/or nucleic acids, are easily degraded under physiological conditions. To alleviate the 
side effect and enhance efficacy, development of delivery carriers that envelop drugs or 
probes is promising and urgent task. 
Nanoparticles have higher solubility, bioavailability and cargo-loading. Nanoparticles 
enhance half-life of cargoes while protecting them from unwanted degradation and 
preventing indiscriminate diffusion. Physicochemical properties of nanoparticles 
determine the circulation and biodistribution (Figure 1.2)2.  
 
Size and shape of nanoparticles 
Size and shape of nanoparticles affect to toxicity, biodistribution and half-life. 
Especially, size and shape are related to uptake of particles. It was reported that 100 nm 
diameter particles were untaken by target cells 2.5 folded higher than 1um diameter 
particles3. Release of cargo is important as well as uptake of particle for delivery system. 
As particles have smaller size, it has higher surface to volume ratio, which means that 
more cargoes are closer to surface of particle. Being near the surface would induce faster 
cargo release4. It would be an advantage for cargo delivery. The size of particles closely 
related to biological pathway. It has been shown that 20nm diameter particles are rapidly  
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Figure 1.1 Timeline of the development of nanomedicine 
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Figure 1.2 Characteristics of nanoparticles as carriers for cargo delivery.  
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removed by renal clearance and over 200nm diameter particles are removed by 
lymphatic systems that are responsible for filtering and clearance of foreign materials5. 
The optimal size of particles is approximately 100nm, which could load enough cargo 
due to high surface to volume ratio and avoid rapid clearance by macrophage dependent 
immune response. 
 
Cargo loading and release 
The size and shape affect properties of nanoparticles, such as bioavailability, 
biodistribution and toxicity. Even if particles get cargo to target site by controlling these 
properties, it cannot be used as carriers unless cargoes cannot be released from particles. 
The release of cargo depends on various factors including temperature, pH, solubility of 
cargo, desorption and diffusion rate of cargo from particles6-7. These factors are 
determined by the type of nanoparticles being used.  
 
Surface modification 
Manipulation of surface of nanoparticles can generate ideal cargo delivery platforms. 
Incorporation of functional material on nanoparticles can induce enhanced stability, 
prevention of aggregation and target-specific delivery8. Nanoparticles are recognized 
foreign materials by lymphatic system, which induces natural immune response. 
Especially, hydrophobic particles are likely to be cleared by indiscriminate binding of 
blood components. Thus, it is important that making hydrophobic nanoparticles to 
hydrophilic to increase circulation time. Various polymers or surfactants or proteins have 
been used for coating materials. PEG is commonly used coating agents, which is 
hydrophilic and inert polymer. PEGylated nanoparticles can block nonspecific binding of 
plasma proteins, preventing substantial clearance under blood circulation. Aggregation 
dependent clearance is also major concern of nanoparticles as well as clearance caused 
by opsonization. Especially, nanoparticles having high surface area such as micelles, 
dendrimers and liposomes are easily aggregated. Various approach has been reported to 
prevent aggregation using coating materials with capping agents and changing the 
surface charge of particles. 
 
Targeted cargo delivery 
 Targeted cargo delivery using nanoparticle is important for minimizing side effect and 
enhancing delivery efficiency. The nanoparticles can penetrate into the damaged tissue 
due to defective epithelial junctions. This leakage of nanoparticles occurs passively. The 
leaked nanoparticles can reach lesion site and deliver cargo, while some nanoparticles 
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reach healthy tissues and induce damage. Thus, active targeting along with passive 
targeting is required in nanoparticle-based cargo delivery. For active targeting, coating 
targeting ligand on nanoparticle is a common strategy. Antibodies, peptides, small 
molecules, aptamers and designed proteins are most common coating materials9. 
Especially, antibodies are widely used as nanoparticle targeting ligand because it is high 
target specificity, bioavailability, longer half-life and other unique in vivo properties. 
Thus, antibodies have been applied to various nanomaterials including lipid vesicles, 
dendrimers, micelles and organic/inorganic nanoparticles. Antibodies are chemically 
conjugated to nanoparticles via modification of antibody fragments and/or modification of 
nanoparticle surfaces. However, chemical modification often causes some limitations, such as 
decreased targeting ability of antibodies and destabilization of the antibodies due to 
modifications of binding sites. 
 
 
1.1.2 Type of nanoparticles 
Liposomes 
 Liposome is the nanomaterials consisting of aqueous core having one or more 
phospholipids and cholesterol layer10. Liposome can load hydrophilic cargo molecules 
into aqueous core region and hydrophobic cargo molecules within the lipid bilayer. In 
addition, composition of liposomes is similar to plasma membrane, resulting in high 
biocompatibility compared to synthetic carriers. Also, modifications of liposome are 
possible using modified lipids and cholesterols to stabilize liposome and add functions on 
interior and exterior surface. Today, several methods to release of drug from liposome 
have been studied using light, heat, enzyme or ultrasound11-14. These liposomes have been 
combined with targeting ligands to develop targeted drug delivery platforms. 
 
Dendrimers 
Dendrimers are macromolecules being nano-sized spherical structure found in nature. 
Dendrimers are composed of four parts: Central core, branches, repeat units at branch 
junction, and terminal capping group15. The branches of dendrimers can load a myriad of 
cargoes due to large surface area and release them eventually. And the large number of 
exposed terminal capping groups having amino acids lead to high biocompatibility and 
longer half-life in blood circulation. Dendrimers are commonly used as a gene delivery 
vectors. Especially, high branched dendrimer-aptamers have high affinity and specificity 
to various kinds of targets16.  
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Micelles 
 Micelles are self-assembled from amphiphilic block copolymers having above the 
critical micelle concentration17. The assembly of copolymer constructs core-shell 
structure. The core consists of hydrophobic parts of polymer, which can load cargo 
molecules and protects them being dissolved. On the other hand, the hydrophilic domains 
including PLA, PLGA and polystyrene form shell structure, which increase the aqueous 
solubility of micelles18-19. In addition, these copolymers are biocompatible and 
biodegradable, therefore micelles are non-toxic carriers for drug delivery system. For 
targeted drug delivery, peptides such as integrin-binding peptide and mitochondria-
targeting peptide were modified to shell domain and selectively target tumors20-21. 
Besides, several micelles have been widely used for gene transfer, temperature and pH 
sensing and photodynamic therapy. 
 
Mesoporous silica nanoparticles 
Various kinds of inorganic nanoparticles have been used in medical imaging and therapy. 
Among the inorganic nanoparticles, mesoporous silica nanoparticles (MSNs) have unique 
properties and potential for biomedical applications. Various morphological structure of MSNs 
can be produced, having different particle size, pore diameter, pore structure, and surface 
functionality in controlled manner. High surface and pore volume of MSNs induces higher 
cargo loading capacity via physical adsorption. In addition, MSNs are inorganic materials that 
protect various types of cargo molecules from environment factors including enzyme 
degradation and hyperthermia. Release of drug on targeted tissues is relatively easy when 
cargo molecules are encapsulated in MSNs compared to other nanomaterials. It is just 
necessary to block the pore entrance to protect cargo molecules using capping materials before 
MSNs reach to lesion sites. When cargo loaded MSNs get into targets, those capping materials 
would detach from pore entrance and trigger the release of cargoes. The stimuli to open the 
pore entrance includes pH, light, heat, and enzymatic cleavage6. Tumor penetration is also 
important factor to treat solid tumor using nanomaterials as well as stimuli dependent cargo 
release. The matrix density is higher than healthy tissues, which block the penetration of 
carriers into the peripheral site of tumor. To enhance tumor penetration, proteolytic enzymes 
grafted on MSNs and these complexes loosen the matrix and get into tumor site22. These 
physicochemical properties cause MSNs as an ideal drug delivery system.  
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1.2 Protein nanoparticle-based delivery 
 
1.2.1 Protein cage architectures 
Various kinds of nanoparticles are used for biomedical applications to diagnose and 
treat diseases. Nanoplatforms have a variety of advantages such as longer half-life in 
blood stream, deep penetration to lesion site, and enhanced cargo loading capacity and 
these properties make nanoparticles as promising delivery carriers. Though various 
nanoplatforms including liposomes, micelles and organic/inorganic nanoparticles are 
developed for drug delivery, these nanoparticles often have heterogenous size, structure 
and composition, high toxicity and low biodegradability, which make it difficult to utilize 
in clinical usage.  
Protein-based nanoparticles are rising delivery nanoplatforms because these particles 
are bio-oriented materials having biocompatibility and solubility by chemical and genetic 
manipulations. Along with these characteristics, protein-based nanoparticles are 
composed of single subunits, inducing same size and structure. Moreover, crystal 
structures of these nanoparticles were already identified, which make it possible to design 
and modify the specific site to give various functionality. Thus, protein-based 
nanoparticles are promising candidates as cargo carriers for diagnosis and therapy. 
Protein cages are self-assembled from multiple copies of single subunits. Most of the 
protein cages form spherical structure having cavity inside nanoparticles. The protein 
cage nanoparticles can be classified to three compartments of exterior, interior and 
interface to impart various functionalities. The cavity provide space to load cargoes such 
as drugs, probes, enzymes, and polymers to protect them from the physiological 
conditions. Exterior of nanoparticles can be modified utilized to attach targeting ligands 
and guest molecules for targeted delivery and interfaces between subunits can be utilized 
for chimeric assembly and/or symmetry broken architectures. Many studies using protein 
cage nanoparticles have been investigated for targeted delivery23. Here, two type of 
protein cage nanoparticles will be discussed. 
 
Lumazine synthase (LS) 
Lumazine synthase is the enzyme which is related to synthesis of riboflavin. Various 
kinds of LSs exist from fungi, archaea and some bacteria24-26. Among the various LSs, we 
focused on lumazine synthase from Aquifex aeolicus (AaLS) which forms icosahedral 
structure (T =1) with an outer diameter of 16 nm and inner diameter of 9 nm27. Based on 
the hollow spherical structure of AaLS, it has been used as nanotemplate to load guest  
molecules. GFP, HIV proteases, and chemical drugs were encapsulated in AaLS and 
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these platforms showed great potential to enhance pharmacological properties of cargo 
molecules. As a versatile drug delivery system, cell-targeting peptides including SP94 
and RGD4C were genetically inserted to surface of AaLS(Figure 1.3)28. Furthermore, 
AaLS maintains stable structure under high temperature and can be easily modified that 
impose various functionalities. 
 
P22 virus-like nanoparticles (P22 VLP) 
 Virus-like particles (VLPs) are commonly used nanoplatforms. Viruses have protein 
shell called capsid, storing and protecting viral nucleic acids from outside. The viral 
capsids are beneficial carriers due to its various size, structure and robust symmetry. The 
virus-like particles are driven from plant viruses (CMV, CCMV and TMV), 
bacteriophage (P22, MS2, and M13) and animal viruses ( HBV, papilomavirus).  
VLP derived from the salmonella typhimurium bacteriophage P22 are self-assembled 
to procapsid from 420 copies of identical coat proteins and 100-300 copies of scaffolding 
protein29. Scaffolding proteins support assembly of coat proteins via noncovalent 
interactions. The unique attribute of P22 VLP is structure change through external stimuli 
and P22 VLP morphologies can be controlled. When P22 self-assemble into the capsids, 
the capsid forms spherical structure, procapsid (PC), including scaffolding protein inside 
the capsid. When scaffolding proteins are eliminated, the capsids retain empty shell (ES) 
morphology. The PC and ES can be transformed to expanded (EX) morphology by heat 
treatments at 65 ºC, causing change of diameter from 56nm to 62nm and decreased pore 
size. Furthermore, heating the capsid at 75 ºC induces the loss of 12 icosahedral 
pentamers, forming 10nm pores at five-fold axis and results in hollow nanostructure 
known as wiffle ball (WB) (Figure 1.4)30.  
P22 VLP is commonly manipulated as cargo vehicles because it has relatively large 
interior space and pore which make it possible to translocate cargo molecules between 
protein shells. Anti-cancer drugs, BTZ and Doxorubicin, were loaded interior surface of 
P22 VLP and hepatocellular carcinoma targeting peptides, SP94, were genetically 
modified to exterior surface31. Besides the small molecules, enzymes were encapsulated 
within P22 VLP to sequester from outside factors. Hydrogenases were encapsulated into 
the P22 VLP to produce hydrogen which is renewable fuels. The new catalytic system 
was sustainable against air, heat or other factors32. Also, P22 VLP has been used for 
intermolecular communications of functional materials due to confined and dense interior 
space. P22 VLP can provide enough space for enzyme cascade because a series of  
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Figure 1.3 Targeted delivery modular platforms using AaLS with targeting peptide. 
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Figure 1.4 Capsid formation and topological change of P22.  
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Figure 1.5 Encapsulation of enzyme cascade within P22 VLP.  
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enzymes can be packed. To mimic sugar metabolism of Pyrococcus furiosus, three 
enzymes including CelB, GALK, and GLUK were co-encapsulated within P22 VLP, 
which system performed a cascade of coupled reaction (Figure 1.5)33. In addition, P22 
VLPs were used as nanotemplates to produce high-density environment using ATRP 
within limited space. This approach was useful to encapsulate lots of catalyst or contrast 
agents that showed better efficiency as more molecules were loaded. 
 
 
1.2.2 Protein engineering 
Protein engineering is the term that developing useful proteins on demand. There are 
many strategies to modify the protein. Here, chemical and genetic modification of 
proteins are introduced. 
 
Chemical modifications 
Chemical modification is powerful tools to conjugate probes, therapeutic drugs, and 
build protein constructs. Cysteine and lysine residues are major targets for the site-
specific modifications. Low abundance of cysteine can cause facile modification of 
single site. Furthermore, the cysteine residue can be removed and inserted by codon 
reassignment. There are various strategies to modify the cysteine residues such as 
aminoethylation, iodoacetamides, maleimides, Dha formation and disulfide formations34-
37. Lysine residue is another choice for modifications where multiple conjugations are 
necessary. For the preferential modifications of amine of lysine, electrophiles including 
activated esters, sulfonyl chlorides or isothiocyanates have been used38-39. In addition, 
unsaturated aldehyde esters react with lysine residues by selective azo-
electrocyclizations40. 
 
Genetic modifications 
  Genetic modification is the direct manipulation of genes. Rational designed DNA is 
made by removing and insertion of the gene materials using recombinant DNA method 
for desired phonotype. Insertion of candidate DNA to host is the widely used genetic 
technique to develop multifunctional fusion proteins. In addition, point mutation which 
changes one or two bases to switch a single amino acid has been also used. The genetic 
modification has been applied in many fields including biomedical research, industry, 
and agriculture. 
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1.2.3 Functional proteins 
Antibody binding domain (Z domain) 
Antibody binding domain named Z domain was engineered from B domain of 
immunoglobulin-binding region of staphylococcal protein A41. B domain has binding 
affinity to both Fc and Fab region, which affect the binding of antibodies to their 
targets. To solve this problem, key amino acids related antibody binding region of B 
domain were mutated and this resulting engineered protein is Z domain42. The Z 
domain has enhanced stability and selective binding affinity to Fc parts of antibodies 
which are isolated from various animal. Using the properties of Z domain, modular 
drug delivery systems have been developed. 
 
Affibody molecules 
  Antibodies is the most common targeting ligands in diagnosis and therapeutics due 
to strong binding and high selectivity to target receptor. However, antibodies have large, 
complex glycosylation pattern and disulfide bond dependent structure, leading to low 
stability and expensive and laborious manufacturing steps. Recently, a variety of artificial 
targeting ligands were developed to replace antibodies. Affibody molecules are one of 
alternative for antibodies (Figure 1.6)43. Affibody molecules consist of 58 amino acids 
without cysteine and has small molecular weight about 6 kDa as well as high solubility 
and stability. Affibody molecules libraries are constructed by genetic modification of 13 
amino acid position of helices one and two of the B domain44-45. These affibody 
molecules showed specific binding to target molecules (e.g TNF-α, EGFR, HER2, IgA, 
IgE and IgM) with strong binding affinity approximately in the µM to pM range46. Some 
affibody molecules having low binding affinity were mutated by helix shuffling or 
sequence alignment. Furthermore, the structural properties including small size and 
simple composition mean that affibody molecules are genetically fused with various 
functional proteins, retaining targeting ability, solubility and stability of fusion proteins47. 
Now, the clinical applications of affibody molecules are explored in diagnostic imaging 
and therapeutics to improve efficiency as an alternative of the conventional antibodies. 
 
Bacterial superglue; SpyTag and SpyCatcher 
  SpyTag and SpyCatcher are driven from the immunoglobulin-like collagen adhesin 
domain (CnaB2) from the fibronectin binding protein FbaB, found in streptococcus 
pygenes48. CnaB2 domain is split into two fragments, which one is N-terminal protein  
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Figure 1.6 Affibody molecules engineered in various formats. 
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fragment named SpyCatcher and the other is C-terminal 13 amino 
acids(AHIVMVDATKPTK) peptide named SpyTag. These two parts spontaneously form 
isopeptide bond between Lys31 of SpyCatcher and Asp117 of SpyTag (Figure 1.7)48. This 
covalent reaction occurs under various pH, temperature, redox conditions and in 
detergents. Also, SpyTag and SpyCatcher maintain reactivity where individual parts are 
located N-terminal, C-terminal and even internal position of protein unlike to other 
tagging proteins. Both SpyTag and SpyCatcher could be fused with functional proteins 
located in vitro and in vivo and maintain the function of fused proteins. Recently, this 
bacterial superglue system has been widely used for biomedical applications. Using the 
SpyTag/SpyCatcher interaction, novel enzyme assemblies are developed (Figure 1.8)49. 
The fusion protein of SpyCatcher and horseradish peroxidase assemble with various 
enzyme complexes, arabinofuranosidase and endoxylanase to enhance sugar conversion 
through spatial proximity of enzymes50. This tool has been also applied for displaying 
functional proteins on surface of bacteria and virus (Figure 1.9)49, 51. Antigens and 
targeting ligands were post-translationally attached to virus-like particle and showed 
improved immune response and gene delivery.  
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Figure 1.7 Isopeptide formation between SpyTag and SpyCatcher. 
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Figure 1.8 Novel enzyme assemblies using SpyTag/SpyCatcher. 
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Figure 1.9 Display functional proteins on viral capsid using SpyTag/SpyCatcher. 
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Chapter 2. Development of an antibody-binding modular nanoplatform for 
antibody-guided targeted cell imaging and delivery 
 
 
2.1 Introduction 
For many biotechnological and biomedical applications and in vivo and/or in vitro diagnostics, target 
specificity and high binding affinity to any given target molecules are essential features. Antibodies have 
extremely high binding affinity and specificity for their target molecules, and a variety of antibodies against 
virtually any desired targets can be readily obtained on demand.1–5 Therefore, antibodies have been widely 
used as ligands for targeted delivery of various therapeutics and/or diagnostics and specific detection of 
biomarkers in vitro and/or in vivo. As targeting ligands, antibodies are generally chemically conjugated to 
functional modules, such as delivery vehicles, enzymes, chemicals, or any other supporting materials.6–
10 However, chemical conjugation and the related approaches often suffer from decreased affinity and 
specificity of antibodies generally due to alterations in their target binding sites or destabilization and 
random orientation of the antibodies.4,11 Therefore, it is necessary to develop a nanoplatform that achieves 
oriented display of antibodies on the surface without the loss of the essential properties of the antibodies: 
high affinity and specificity. In addition, a potential nanoplatform should have structural plasticity that 
acquires additional functionalities on demand as well as a structural uniformity that ensures reproducible 
outcomes. 
Lumazine synthase protein cage nanoparticle isolated from the hyperthermophile Aquifex 
aeolicus (AaLS) is a nanocage-forming enzyme that consists of 60 identical subunits with an exterior 
diameter of 15.4 nm and an 8 nm interior cavity,12 and catalyzes the penultimate step in the synthesis of 
riboflavin.13 Its hollow spherical architecture has been used as a template for the encapsulation of cargo 
proteins, such as green fluorescent protein,14,15 HIV protease,16 and ferritin,17 by engineering the electrostatic 
properties of its interior surface and the biomineralization of iron oxide nanoparticles.18 AaLS has also been 
utilized as a building block for fabricating uniform layer-by-layer (LbL) assemblies19 and as a nanoplatform 
for developing a versatile drug delivery vehicle.20,21 Similar to the other protein cage nanoparticles, such as 
ferritin, virus-like particles and encapsulin, AaLS has a uniform size distribution and a symmetric and well-
defined multivalent structure.12 Furthermore, AaLS exhibits an unusual heat stability and genetic and 
chemical versatility that allows it to acquire multiple functionalities simultaneously.19–21 
In this study, we constructed a universal multivalent antibody-binding nanoplatform by genetically 
introducing antibody-binding domains (ABDs) to the surface of lumazine synthase protein cage 
nanoparticles isolated from the hyperthermophile Aquifex aeolicus (AaLS). We demonstrate that the 
resulting ABD–AaLS effectively captures various types of antibodies derived from diverse species on 
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demand, and that their complexes selectively recognize and bind to their target cells in vitro, guided by 
antibodies displayed on the surface of ABD–AaLS (Scheme 2.1). 
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Scheme 2.1 Construction of ABD-AaLS protein cage nanoparticle and its application for fluorescent 
cell imaging as polyvalent antibody-displaying nanoplatforms. 
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2.2 Materials and Methods 
 
Construction and purification of antibody-binding domain displaying AaLS (ABD–AaLS) protein 
cage nanoparticles 
The IPTG inducible pET-30b based plasmids containing genes encoding wild-type AaLS protein was 
prepared and used as templates. The optimized antibody-binding domain (ABD) was synthesized and 
subcloned into the C-terminus of AaLS gene with extra linker residues. We introduced 26 amino acid 
residues to provide sufficient flexibility and space for antibody binding. The amplifed DNAs were 
used to transform the competent E. coli strain BL21 (DE), resulting in the overexpression in E. coli of 
the ABD–AaLS protein cage nanoparticles. 
 
Quartz crystal microbalance (QCM) measurements 
QCM experiments were performed using Q-Sense E4 and standard gold QCM sensors (Q-Sense, 
Sweden) as described previously, with slight modifications.4 Briefly, the system was operated in flow 
mode with a pump and temperature was maintained at 25.0 ± 0.1 C. Each sample solution was 
introduced to the measurement chamber with a pump and continuously measured for 10 min prior to 
the subsequent introductions. AaLS and ABD–AaLS and various IgGs (rabbit, rat, and mouse) were 
introduced at concentrations of approximately 100 mg ml-1 and 50 mg ml-1, respectively, in phosphate 
buffer (50 mM phosphate, 100 mM NaCl, pH 6.5). Resonance frequencies were measured 
simultaneously at seven harmonics (5, 15, 25, 35, 45, 55 and 65 MHz). For clarity, only the 
normalized frequency of the third overtone is shown. 
 
Surface plasmon resonance (SPR) analysis 
SPR experiments were performed with carboxyl dextran CM5 gold chips on a Biacore 3000 device 
(Biacore AB, Sweden) at 25 C using a PBS buffer as a running solution. Rabbit, rat, or mouse IgGs 
were coupled to the surface of a CM5 sensor chip by standard amine-coupling chemistry on the SPR 
instrument as described previously, with slight modifications.4,22 Briefly, a mixture of EDC (0.4 M) 
and NHS (0.6 M) was injected onto the chip at a flow rate of 10 ml min-1 to activate carboxyl groups 
on the sensor surface and subsequently 20 mg ml-1 of rabbit, rat, or mouse IgGs were added at the 
same flow rate for 7 min. Excess reactive groups were blocked with 1 M ethanolamine (pH 8.0). 
ABD–AaLS captures by rabbit, rat, or mouse IgGs were examined by applying various amounts (30, 
60, 120, 240, and 400 nM) of ABD–AaLS (PBS, pH 7.4) to the surface at a flow rate of 30 ml min-1. 
AaLS was applied in parallel as a control. 
 
Cell culture and fluorescence cell microscopy 
SKBR3 was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and SCC-7 
36 
 
and KB cells were obtained from the Korean cell line bank (KCLB). SKBR3 cells were cultured in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum 
(FBS, Invitrogen Corp., Carlsbad, CA) and antibiotics (100 mg ml-1 penicillin and 50 mg ml-1 
streptomycin) at 37 C under 5% CO2. SCC-7 cells were cultured in RPMI1640 supplemented with 10% 
FBS and 1% penicillin–streptomycin and KB cells were cultured in RPMI1640 medium with L-
glutamine (300 mg l-1), 10% FBS, 25 mM HEPES and 25 mM NaHCO3. SKBR3, SCC-7, and KB 
cells (2 x 104 per well) were grown in 8-well microscopy chambers (Ibidi GmbH, Martinsried, 
Germany). -1 The combinations of fABD–AaLS (final 50 nM) and Alexa-HER2-Ab or HER2-Ab 
(rabbit IgG, final 200 nM), fABD–AaLS (final 50 nM) and Alexa-CD44-Ab or CD44-Ab (rat IgG, 
final 200 nM), or fABD–AaLS (final 50 nM) and Alexa-integrin-Ab or integrin-Ab (mouse IgG, final 
200 nM) were mixed in DMEM supplemented with 10% (v/v) FBS, antibiotics, and 0.05% Tween 20, 
and incubated at room temperature for 30 min. The individual mixtures of fABD–AaLS and various 
IgGs were added to corresponding cell culture wells and incubated at 37 C for 30 min. The cells were 
washed three times with PBS containing 0.05% Tween 20 and mixed with 4% paraformaldehyde at 
room temperature for 20 min, and again washed with PBS. The cells were incubated with 4,6-
diamidino-2-phenylindole (DAPI, Sigma) in PBS for 10 min and washed with PBS. Fluorescence 
images are obtained using a Personal DV microscope (Applied Precision, Washington, USA). 
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2.3 Results and discussion 
We first synthesized a gene that encodes the ABD of protein A to construct an AaLS-based multivalent 
antibody-binding nanoplatform. Protein A and G have been widely used as ligands for purifying various 
types of antibodies, because they selectively capture antibodies with high affinity.11,26 In particular, the ABD 
of protein A (the so-called Z-domain) is known to exclusively bind to the Fc region of various types of 
antibodies.27–30 We also genetically engineered AaLS by replacing arginine 108 with cysteine (R108C) for 
later use in site-specific modification with diagnostic probes such as fluorescent dyes.19–21 Subsequently, we 
fused the ABD nucleic acid sequence to the 3′ end of the AaLS gene with intervening linker residues 
(KDPNSGGGLVPRGSGGGSGGGTGGGSGGG) to provide flexibility and room for antibody 
accessibility. We previously reported that the C-termini of AaLS expose on the surface of protein cage 
nanoparticles and tolerate the insertion of oligopeptides.19–21 However, this is the first time that a domain of 
this size (59 amino acids) has been introduced. 
We overexpressed the ABD–AaLS and successfully purified them without significant loss of materials. 
We confirmed the fusion of the ABD and AaLS using DNA sequencing and mass spectrometric analysis. 
Compared with the mass of the dissociated AaLS monomer (16 652.5 Da), the dissociated subunit mass of 
ABD–AaLS (25 557.0 Da) showed an increase of 8904.5 Da, which exactly corresponds to the combined 
mass of the ABD and linker (calc. 8904.5 Da) (Figure 2.1A). In addition, the ABD fused to the C-terminus 
of AaLS did not significantly alter its original protein cage architecture. Transmission electron microscopic 
(TEM) images revealed a cage-like architecture with a diameter of approximately 15 nm, which is almost 
identical to that of AaLS (Figure 2.1B). Since the ABD is relatively small and lacking in electron density, it 
was not readily apparent in the TEM images. However, ABD–AaLS eluted much earlier than AaLS in size-
exclusion chromatography (Figure 2.1C), consistent with a larger hydrodynamic diameter due to the 
addition of ABDs on the surface of AaLS. Dynamic light scattering analysis of ABD–AaLS confirmed a 
larger hydrodynamic diameter (18.3 nm) than that of AaLS (15.8 nm) (Figure 2.1D). These results indicate 
that ABD–AaLS forms an intact protein cage architecture uniformly displaying ABDs on the surface of 
AaLS. In order to investigate whether the displayed ABDs on the AaLS effectively capture various types of 
antibodies, we first monitored interactions between antibodies and ABD–AaLS in real time by quartz 
crystal microbalance (QCM). Deposition and release of molecules on the QCM sensor induce decreases and 
increases in resonance frequency (−ΔF), respectively, and these changes are sensitive to the masses of the 
deposited or released molecules.31 We previously showed that wild type and AaLS variants stably form a 
uniform monolayer on a gold QCM sensor without any surface modifications.4,19,32-33 ABD–AaLS also 
strongly bound to the gold QCM sensor to form a uniform monolayer and remained bound even after 
washing with buffer (Figure 2.1E). The resonance frequency of the ABD–AaLS monolayer dramatically 
decreased upon the addition of rabbit IgG, whereas that of the AaLS monolayer was unchanged (Figure 
2.1E). Even extensive buffer washing did not remove the initially bound rabbit IgGs (Figure 2.1E). 
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Figure 2.1 Characterization of ABD–AaLS. (A) Molecular mass measurements of the dissociated subunits 
of AaLS (calc. 16 652.2 Da; obs. 16 652.5 Da, bottom) and ABD–AaLS (calc. 25 556.8 Da; obs. 25 557.0 
Da, top). (B) Transmission electron micrographic (TEM) image of 2% uranyl acetate stained ABD–AaLS. 
(C) Size-exclusion elution profiles of AaLS (bottom) and ABD–AaLS (top). (D) Dynamic light scattering 
measurements of AaLS (bottom) and ABD–AaLS (top). The mean diameters of AaLS and ABD–AaLS 
were 15.80 and 18.30 nm, respectively. (E) QCM resonance signal changes (−ΔF) upon introduction of 
either AaLS (dashed line) or ABD–AaLS (solid line) onto the surface of standard gold sensors (closed arrow) 
and subsequent deposition of rabbit IgG on the monolayers of either AaLS (dashed line) or ABD–AaLS 
(solid line) (open arrow). (F) SPR analyses of ABD–AaLS binding to rabbit IgG immobilized SPR gold 
sensors. Various concentrations of ABD–AaLS (30, 60, 120, 240, and 480 nM) were loaded to the rabbit 
IgG immobilized SPR gold sensor at a flow rate of 5 μl min−1 for 2 min (closed arrow) and subsequently 
buffers were added (open arrow) and flow maintained for 8 min. 
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To further investigate the binding affinity between ABD–AaLS and rabbit IgGs, we performed surface 
plasmon resonance (SPR) analyses. In contrast to QCM studies, we first immobilized rabbit IgGs on the 
surface of an SPR CM5 sensor chip and then introduced ABD–AaLS at several different concentrations 
(Figure 2.1F). Each experiment was performed after regeneration of the free-IgG surface by base washing 
of ABD–AaLS bound to the IgG on the chip and subsequent equilibration with the appropriate binding 
buffer.34 Gradual increases in SPR responses (RU) were observed upon introduction of ABD–AaLS at 
various concentrations (Figure 2.1F), whereas no apparent change was observed upon introduction of AaLS. 
Consistent with previous QCM results, apparent release of bound ABD–AaLS from the immobilized IgGs 
was not observed even after extensive buffer washing (Figure 2.1F). These data suggest that the polyvalent 
display of ABDs on the surface of AaLS protein cage nanoparticles may allow them to capture IgGs 
cooperatively while tightly maintaining antibody/ABD–AaLS (Ab/ABD–AaLS) complexes. 
To investigate whether Ab/ABD–AaLS complexes can selectively bind their target cells guided by bound 
antibodies, we prepared target cell lines and selected corresponding monoclonal antibodies that recognize 
these cells. First, we prepared the SKBR3 breast cancer cell line and chose an anti-HER2 antibody as a 
model rabbit IgG, since HER2 is known to be overexpressed on the surface of SKBR3 cells and has been 
extensively utilized as a ligand for targeted delivery and therapy.35,36 We first prepared Alexa Fluor 647-
labeled anti-HER2 monoclonal antibodies (Alexa-HER2-Ab) and fluorescein-labeled ABD–AaLS (fABD–
AaLS). Mass spectrometric analysis revealed that all the subunits were labeled with one fluorescein (60 
fluorescein molecules per ABD–AaLS nanoparticle) (Figure 2.2A). Fluorescein conjugation did not 
significantly alter their cage architecture (Figure 2.2B and C).  
Subsequently, we simply mixed Alexa-HER2-Ab and fABD–AaLS to form Alexa-HER2-Ab/fABD–
AaLS complexes. These complexes were incubated with SKBR3 cells and visualized and analyzed by 
fluorescence microscopy and flow cytometry. fABD–AaLS and Alexa-HER2-Ab alone were used as 
negative and positive controls, respectively. While Alexa-HER2-Ab/fABD–AaLS complexes and Alexa-
HER2-Ab bound to SKBR3 cells (Figure 2.3A and B), fABD–AaLS alone did not (Figure 2.3D). 
Fluorescence images of Alexa-HER2-Ab (Figure 2.3A, red, middle panel) and fABD–AaLS (Figure 2.3A, 
green, left panel) indicated their colocalization, which was confirmed in merged images (Figure 2.3A, right 
panel). Furthermore, when we treated SKBR3 cells with a complex of unlabeled HER2-Ab and fABD–
AaLS, the cells were well visualized with HER2-Ab/fABD–AaLS complexes without fluorescent labeling 
of antibodies (Figure 2.3C). Flow cytometry measurements of Alexa-HER2-Ab, Alexa-HER2-Ab/fABD–
AaLS complexes, and HER2-Ab/fABD–AaLS complexes revealed virtually identical levels of cell binding, 
quantitatively confirming their cell-specific binding (Figure 2.3E). These data demonstrate that anti-HER2 
antibodies on the surface of fABD–AaLS allow these complexes to recognize HER2 expressed on the 
surface of SKBR3 cells and selectively bind to them. These data also imply that ABD–AaLS serves as a 
nanoplatform that not only displays targeting antibodies on the surface in an orientation-controlled manner 
but also acquires fluorescent probes effectively, and that they can be used as target-specific cell imaging 
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Figure 2.2 Characterization of fluorescent dye (fluorescein) labeled ABD-AaLS (fABD-AaLS). (A) 
Molecular mass measurements of the dissociated subunits of ABD-AaLS (calc. 25556.8 Da; obs. 
25557.0 Da, bottom) and fABD-AaLS (calc. 25984.2 Da; obs. 25983.0 Da, top). Molecular mass 
increase (427.0 Da) upon labeling agreed excellent with molecular mass of fluorescein-5-maleimide 
(427.4 Da) (B) Size exclusion elution profiles of ABD-AaLS (bottom) and fABD-AaLS (top). fABD-
AaLS eluted same time as that of untreated ABD-AaLS. Significant absorption increase at 495 nm is 
due to the attached fluoresceins. (C) Transmission electron micrographic (TEM) image of 2% uranyl 
acetate stained fABD-AaLS. fABD-AaLS maintained its cage architecture even after chemical 
conjugation of fluorescein. 
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Figure 2.3 Florescence microscopic images (A–D) and flow cytometry measurements (E–H) of SKBR3 
breast cancer cells treated with Alexa-HER2-Ab/fABD–AaLS complexes (A and E), Alexa-HER2-Ab only 
(B and F), HER2-Ab/fABD–AaLS complexes (C and G), and fABD–AaLS only (D and H). Rabbit anti-
HER2 IgG and ABD–AaLS were labeled with Alexa Fluor 647 (Alexa-HER2-Ab, red) and fluorescein 
(fABD–AaLS, green), respectively, and nuclei were visualized with DAPI as blue. Fluorescein (left rows), 
Alexa Fluor 647 (middle rows), and merged with DAPI staining (right rows) are shown. 
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probes. 
To examine whether ABD–AaLS can serve as a universal antibody-binding nanoplatform for target-
selective cell imaging by displaying various types of targeting antibodies (IgGs) on the surface in an 
orientation-controlled manner, we adapted two other types of antibodies derived from rat and mouse 
individually. The ability of ABD–AaLS to bind to rat and mouse IgGs was validated by QCM and SPR 
analyses. QCM and SPR studies were performed under the same conditions as those for rabbit IgG, and the 
patterns of rat and mouse IgGs binding to the ABD–AaLS monolayer on the QCM sensor were virtually 
identical to those of rabbit IgG (Figure 2.4A and B). For SPR experiments, rat or mouse IgGs were 
immobilized on the surface of an SPR CM-5 sensor chip instead of rabbit IgG, followed by application of 
ABD–AaLS at a series of concentrations. The patterns of SPR responses were also similar to those of rabbit 
IgG (Figure 2.4C-F), suggesting that rat and mouse IgGs also bind strongly to ABD–AaLS but not to AaLS 
as rabbit IgG does. 
To confirm specific binding between the non-covalent complexes consisting of ABD–AaLS and rat or 
mouse IgGs to the target cells, we chose anti-CD44 monoclonal antibody and anti-integrin αβγ3 monoclonal 
antibody as rat- and mouse-derived IgGs, respectively. We performed fluorescence cell imaging and flow 
cytometry under the same conditions as those for Alexa-HER2-Ab/fABD–AaLS. We prepared Alexa Fluor 
647-labeled anti-CD44 Ab (Alexa-CD44-Ab) and anti-integrin αβγ3 Ab (Alexa-integrin-Ab), unlabeled anti-
CD44 Ab (CD44-Ab) and anti-integrin αβγ3 Ab (integrin-Ab), and fluorescein-labeled ABD–AaLS (fABD–
AaLS), and we subsequently mixed each Ab and fABD–AaLS to form Ab/fABD–AaLS complexes with 
various combinations as described above. The resulting Alexa-CD44-Ab/fABD–AaLS and CD44-
Ab/fABD–AaLS or Alexa-integrin-Ab/fABD–AaLS and integrin-Ab/fABD–AaLS complexes were 
incubated with SCC-7 cells, which overexpress the cell-surface glycoprotein CD44 that is involved in cell–
cell interactions and cell adhesion and migration,37,38 or KB cells, which overexpress integrin αγβ3 on their 
surface.39 The cells were then examined by fluorescence microscopy and flow cytometry (Figure 2.5 and 
Figure 2.6). Similarly to rabbit IgG, Alexa-CD44-Ab/fABD–AaLS and Alexa-integrin-Ab/fABD–AaLS 
complexes selectively bound to SCC-7 cells and KB cells, respectively (Figure 2.5A,E and Figure 2.6), and 
the fluorescence signals of fABD–AaLS (Figure 2.5A, green, left panel) and Alexa-CD44-Ab (Figure 
2.5A, red, right panel) overlapped to each other (Figure 2.5A, right panel). Alexa-CD44-Ab and CD44-
Ab/fABD–AaLS complexes also tightly bound to SCC-7 cells (Figure 2.5B,C and E). ABD–AaLS was 
alternatively labeled with Alexa Fluor 647 and subsequently complexed with unlabeled CD44-Ab. These 
complexes also tightly bound to SCC-7 cells (Figure 2.7), suggesting that ABD–AaLS is amenable to 
chemical modifications with various types of fluorophores. 
To examine the efficacy of antibody-guided targeted drug delivery with ABD–AaLS, the 6-
maleimidocaproyl hydrazone prodrug of doxorubicin (AlDox)40 was chemically conjugated to ABD–AaLS 
(ABD–AaLS–AlDox) instead of fluorophores as described previously.20,25 Subsequently, targeting 
antibodies were non-covalently complexed with ABD–AaLS–AlDox (Ab/ABD–AaLS–AlDox) depending  
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Figure 2.4 QCM resonance signal changes (-ΔF) upon introductions of either AaLS (dashed line) or 
ABD-AaLS (solid line) onto the surface of standard gold sensors (closed arrow) and subsequent 
deposition of rat (A) or mouse (B) IgGs on the monolayers of either AaLS (dashed line) or ABD-
AaLS (solid line) (open arrow). SPR analyses of ABD-AaLS or AaLS binding to rat (C and D) or 
mouse (E and F) IgG immobilized SPR gold sensors. Various amounts of ABD-AaLS (C and E) or 
AaLS (D and F) (30, 60, 120, 240, and 480 nM) were loaded to the rat or mouse IgG immobilized 
SPR gold sensor at a flow rate of 5 μl/min for 2 min (closed arrow) and subsequently buffers were 
added (open arrow) and kept flow for 8 min. 
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Figure 2.5 Florescence microscopic images (A–D) and flow cytometry measurements (E–H) of SCC-7 
cells treated with Alexa-CD44-Ab/fABD–AaLS complexes (A and E), Alexa-CD44-Ab only (B and F), 
CD44-Ab/fABD–AaLS complexes (C and G), and fABD–AaLS only (D and H). Rat anti-CD44 IgG and 
ABD–AaLS were labeled with Alexa Fluor 647 (Alexa-CD44-Ab, red) and fluorescein (fABD–AaLS, 
green), respectively, and nuclei were visualized with DAPI as blue. Fluorescein (left rows), Alexa Fluor 647 
(middle rows), and merged with DAPI staining (right rows) are shown. 
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Figure 2.6 Florescence microscopic images (A-D) and flow cytometry measurements (E-H) of KB 
cells treated with Alexa-integrin-Ab/fABD-AaLS complexes (A and E), Alexa-integrin-Ab only (B 
and F), integrin-Ab/fABD-AaLS complexes (C and G) and fABD-AaLS only (D and H), respectively. 
Mouse anti-integrin IgG and ABD-AaLS were labeled with Alexa-647 (AlexaCD44-Ab, red) and 
fluorescein (fABD-AaLS, green), respectively, and nuclei were visualized with DAPI as blue. 
Fluorescein (left rows), Alexa-647 (middle rows), and merged with DAPI staining (right rows) were 
presented. 
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Figure 2.7 Florescent microscopic images of SCC-7 cells treated with Alexa-ABD-AaLS only (top 
two panels) and CD44-Ab/Alexa-ABD-AaLS complexes (bottom two panels), respectively. ABD-
AaLS were labeled with Alexa-647 (Alexa-ABD-AaLS, red) and nuclei were visualized with DAPI as 
blue, whereas rat anti-CD44 IgG was not labeled with any dyes at all. Alexa-647 (left rows) and DAPI 
staining (right rows) were presented. 
.  
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on target cells and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability 
assays were performed. Hydrazine linkage is known to be quite stable at neutral pH and to become quickly 
cleaved under an acidic condition (pH 4.5–5.5).40 We previously showed that 48 AlDox molecules are 
conjugated to one AaLS (60 subunits) and approximately 65% of them are released within 15 h.20 
The SKBR3, SCC-7 and KB cells were treated with the complexes of anti-HER2-Ab, anti-CD44-Ab, or 
anti-integrin-Ab and ABD–AaLS–AlDox, respectively, for 1 h. The free prodrug, AlDox, and ABD–AaLS 
only were also treated in parallel to serve as positive and negative controls. One hour later, cells were 
washed with fresh media to remove unbound complexes and free AlDox, further cultured for 48 h, and their 
viability was measured to investigate the cytotoxicity of delivered drugs. The cytotoxic effects of delivered 
AlDox on antibody-corresponding target cells significantly increased in a dose-dependent manner and were 
higher than even those of free AlDox, whereas ABD–AaLS without AlDox had no significant effect on cell 
viability (Figure 2.8). The enhanced cytotoxicity of antibody-mediated ABD–AaLS–AlDox may be due to 
receptor-mediated endocytosis of whole complexes upon specific binding, which transports increased 
amounts of AlDox into the target cells, and subsequent low pH-induced release of Dox into the cells. 
Taken together, these results indicate that ABD–AaLS can serve as a universal IgG-binding nanoplatform 
for efficiently displaying IgGs derived from a variety of species, such as rabbit, rat, and mouse, on demand 
by simple molecular recognition, and those complexes can be used as not only effective optical probes for 
target-specific cell imaging but also drug-carriers for target-specific treatment. 
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Figure 2.8 MTT cell viability assay. (A) Dose-dependent cytotoxicity profiles of anti-HER2-Ab/ABD–
AaLS–AlDox (black, squares), free AlDox (red, circles), and ABD–AaLS only (blue, triangles) toward 
SKBR3 cells. (B) Dose-dependent cytotoxicity profiles of anti-CD44-Ab/ABD–AaLS–AlDox (black, 
squares), free AlDox (red, circles), and ABD–AaLS only (blue, triangles) toward SCC-7 cells. (C) Dose-
dependent cytotoxicity profiles of anti-integrin-Ab/ABD–AaLS–AlDox (black, squares), free AlDox (red, 
circles), and ABD–AaLS only (blue, triangles) toward KB cells. 
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2.4 Conclusion 
In this study, we constructed a polyvalent antibody-binding nanoplatform, ABD–AaLS, and 
demonstrated that ABD–AaLS effectively captures various types of antibodies derived from diverse species 
on demand. We also successfully demonstrated that targeting antibody/ABD–AaLS complexes selectively 
recognize and bind to their target cells in vitro, guided by antibodies displayed on the surface of ABD–
AaLS. 
Antibodies offer an almost unlimited range of specific targeting moieties, making them attractive 
targeting ligands for in vitro and/or in vivo diagnostics.1,2,5,41 Depending on the target cells, appropriate 
antibodies can be selected and simply mixed with ABD–AaLS, which can be independently pre-modified 
depending on the purposes, to form diagnostic probe complexes. Utilizing ABD–AaLS as a universal 
antibody-binding nanoplatform, we can overcome the drawbacks associated with chemical conjugation of 
antibodies through non-covalent complexation as well as introduce additional functionalities to ABD–AaLS 
without altering antibody activity. Since ABD–AaLS has an additional internal cavity and exterior sites for 
encapsulation and attachment of cargo molecules such as drugs and diagnostic probes, ABD–AaLS may 
provide new opportunities to develop versatile target-dependent theranostic delivery systems. 
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 Chapter 3. Development of target-tunable P22 VLP-based delivery 
nanoplatforms using bacterial superglue 
 
 
3.1 Introduction 
 
The targeted delivery of diagnostics and/or therapeutics is a powerful approach for early diagnosis 
and treatment of disease in the biomedical field. Protein cage nanoparticles have been widely used as 
targeted delivery vehicles for diagnostic and therapeutic applications 1-5, because they have well-
defined, highly symmetrical structures of uniform size and shape, with a simple composition 
comprising multiple copies of one or two protein subunits, and a plasticity which enables them to be 
manipulated both genetically and chemically. The interior cavities and surfaces of protein cage 
nanoparticles are generally loaded with cargo molecules including drugs, fluorescent dyes, antigens, 
contrast agents, enzymes, and polymers, using self-assembly mediated encapsulations and/or chemical 
conjugations 6-13. The exterior surface is frequently used to display targeting ligands 2. Small targeting 
ligands, such as RGD and SP94 peptides or folic acids, have been displayed via direct genetic fusion 
or chemical conjugation on the exterior of protein cage nanoparticles 2, 14-15. However, these 
approaches are only suitable for small peptides or chemicals, not for whole protein or domain ligands. 
Direct genetic fusion of whole proteins or domain ligands frequently results in disruption of the 
supramolecular architecture of protein cage nanoparticles, inducing aggregation and/or improper 
folding of the protein cage nanoparticles 16-17. Thus, it is necessary to develop an easy method for 
displaying large proteins or domain ligands on the surface of protein cage nanoparticles. 
In this study, we constructed target-tunable and cargo-loadable modular delivery nanoplatforms 
using P22 virus-like particles (VLPs); displayed two different targeting ligands on their surface; 
tailored to their target cells using a bacterial superglue, the SpyTag/SpyCatcher (ST/SC) post-
translational ligation system; and loaded prodrugs on either interior or exterior surfaces on demand 
(Scheme 3.1).  
Salmonella typhimurium bacteriophage P22 VLP self-assembles from 420 copies of the coat protein, 
with the aid of approximately 300 scaffolding proteins. It forms T=7 icosahedral hollow nanoparticles 
with an outer diameter of 56 nm 18. P22 VLPs have been widely utilized as nanoplatforms for 
delivering cargo molecules in a target-specific manner 15, 19 by encapsulating functional proteins 
within their interior cavity 12, because of their large, robust, and versatile structure, which can be 
created by easy heterologous expression. Recently, a sortase tag, LPETG, was genetically introduced 
into the C-terminus of the P22 capsid and an N-terminally polyglycine-tagged GFP or head domain of 
the influenza hemagglutinin protein (HAhead) were post-translationally attached using sortase-
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mediated ligation 20. We used the ST/SC post-translational ligation system to produce P22 VLPs 
displaying relatively large targeting ligands on their surfaces, without altering the protein cage 
nanoparticle architecture. SpyTag (ST) and SpyCatcher (SC) are split proteins derived from the 
Streptococcus pyogenes fibronectin-binding protein FbaB. The SpyCatcher protein recognizes 13 
amino acids (AHIVMVDAYKPTK) of SpyTag, and they form a covalent isopeptide bond 21. This 
reaction is rapid and selective and occurs under a range of pH, buffer, and temperature conditions 
upon mixing, without the need for additional chemical compounds or enzymes. Previously, we 
constructed a series of multifunctional protein conjugates by combining either various affibody 
molecules 22-24 and fluorescent proteins or enzymes and clustering ligands post-translationally in a 
mix-and-match manner. We also demonstrated that those conjugates exhibited a range of different 
functions 22, 24-25. The ST/SC protein ligation system has been applied for displaying various antigenic 
proteins and targeting ligands on virus-like particles and their effective immune response inductions 
and cell-specific gene delivery were successfully demonstrated26-34.  
In the research reported here, we developed target-tunable P22 VLP-based polyvalent delivery 
nanoplatforms, ligated two different targeting affibody molecules on demand, chemically conjugated 
pH-sensitive prodrugs, and evaluated them as drug delivery platforms to bind target receptors and 
selectively kill target cells in vitro. 
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Scheme 3.1 Schematic representation of various configurations of target‐tunable and cargo‐loadable 
P22 VLP‐based delivery nanoplatforms. Red dots on the interior (bottom) and exterior (top) surface of 
particles represent either prodrugs or fluorescent dyes. HER2Afb and EGFRAfb are represented as 
blue and yellow surface models, respectively. VLP, virus‐like particles 
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3.2 Materials and Methods 
Genetic modifications and purifications of P22 WB-ST and SC-Afb 
SpyTag peptide (AHIVMVDAYKPTK) with extra amino acids (SGGGSGGG) were genetically 
added to C-terminus of P22 capsid protein by well-established polymerase chain reaction (PCR). 
Either lysine residue at position 118 or serine residues at position 113 of P22 capsid protein was 
genetically substituted with cysteine (P22in VLP-ST or P22ex VLP-ST). P22 VLP-ST (P22in VLP-ST 
and P22ex VLP-ST) genes were subcloned in pET30a vector, transformed to E.coli strain BL21(DE3), 
and overexpressed at 37 ℃ for 16 hrs in a shaking incubator. P22 VLP-ST were sedimented with 35% 
sucrose cushion and recovered by slow resuspension with buffer. Resuspended P22 VLP-ST were 
further heated at 75 ℃ for 15 min to obtain P22 WB-ST. P22 WB-ST were further purified by 10-35% 
sucrose gradient 18. On the other hands, SpyCatcher protein was genetically fused to N-termini of 
epidermal growth factor receptor (EGFR) affibody molecules or human epidermal growth factor 
receptor2 (HER2) affibody molecules with extra amino acids (SGGGSGGG) by PCR. SC-Afb (SC-
EGFRAfb and SC-HER2Afb) in pETDuet vector were transformed to E.coli strain BL21(DE3) and 
overexpressed at 30 ℃ for 16 hrs in shaking incubator. SC-Afb were purified by immobilized metal 
affinity chromatography (IMAC) 24. Purified proteins were dialyzed against with phosphate-buffered 
saline (PBS, pH7.4). 
 
Characterization of purified P22 WB-ST and P22 WB-ST/SC-Afb 
Concentrations of P22 WB‐ST and SC‐Afb in PBS (pH 7.4) were determined by the BCA assay. 
P22 WB‐ST were mixed with various amounts of SC‐Afb and incubated for various times at room 
temperature to obtain the optimal reaction condition. Reactions were stopped at indicated times by 
adding SDS loading buffer and boiling at 110℃. Reaction products were analyzed with SDS‐PAGE 
and optimal condition of input ratio of SC‐Afb to P22 WB‐ST subunit was determined as 0.4 and 
reaction was finished within 30 min. Hydrodynamic diameters of P22 WB‐ST and P22 WB‐ST/SC‐
Afb were measured with dynamic light scattering (DLS; Zetasizer, Malvern). Each sample was 
prepared at 1 mg/ml concentration and set in disposable rectangular polystyrene cuvette. The scattered 
light was detected by a 90° angle with the projected light at 25℃. P22 WB‐ST and P22 WB‐ST/SC‐
Afb were also negatively stained with 2% uranyl acetate and images were obtained with transmission 
electron microscope (TEM). P22‐ST were stable in PBS at 4℃ for a month and SC‐Afb were stable at 
−20℃ for 6 months. 
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Cell culture and fluorescent microscope imaging 
MDA‐MB‐468 and MCF‐10A cells were purchased from American Type Culture Collection 
(ATCC) and SK‐BR3 and MCF‐7 cells were purchased from Korean cell line bank (KCLB). MDA‐
MB‐468 cells were cultured in Leibovitz's L‐15 medium with 10% fetal bovine serum (FBS), 1% 
antibiotic‐antimycotic, 25 mM HEPES and sodium bicarbonate. SK‐BR‐3 cells were cultured in 
DMEM medium with 10% FBS and 1% antibiotic‐antimycotic. MCF‐7 cells were cultured in RPMI‐
1640 with 10% FBS and 1% antibiotic‐antimycotic. MCF‐10A cells were cultured in DMEM/F12 
with 5% horse serum, 1% penicillin/streptomycin, EGF, hydrocortisone, insulin, and 25 mM 
bicarbonate. All cells were grown in 5% CO2 and 95% air at 37℃. 1 × 105 cells were grown on 
microscope cover glass in a 12‐well plate for overnight to perform fluorescent microscopic imaging. 
The cells were fixed by 4% paraformaldehyde in PBS. Subsequently, blocking buffer (5% BSA, 5% 
FBS, and 0.5% Triton X‐100 in PBS) were treated for 1 hr at room temperature with gentle shake to 
prevent the nonspecific binding of samples to the background. Ten micrometers of the samples were 
added to fixed cells and incubated for 1 hr at room temperature. Before sealing, the cells were washed 
by wash buffer (0.1% Triton X‐100 in PBS) three times and the nuclei were stained by DAPI. Images 
of samples were acquired by Olympus Fluoview FV1000 fluorescent microscope (Olympus, UOBC). 
 
Cytotoxic assay 
The in vitro cytotoxicity of Aldoxorubicin (AlDox) conjugated samples was measured by the 
thiazolyl blue tetrazolium bromide (MTT; Sigma‐Aldrich) assay. 1 × 104 cells were cultured in 96‐
well plates for overnight. Serially diluted samples from 20 μM to 1.2 μM were treated to cells under 5% 
CO2 at 37℃ for 1 hr. The cells were washed with fresh media two times and grown for additional 3 
days. The cells were treated with 200 μl of media containing 0.5 mg/ml of MTT for 3 hrs, media were 
removed, and the cells were resuspended with dimethyl sulfoxide (DMSO) to dissolve formazan 
crystals formed in viable cells. Dissolved formazan was monitored by measuring absorbance at 
595 nm with multi‐scanner (Spectramax, Molecular devices). 
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3.3 Results and discussion 
 
SpyTag was genetically fused to the C-terminus of the P22 viral capsid, which is known to be 
exposed to the exterior 35 to form P22 VLP-ST. One amino acid located on either the interior or 
exterior surface of P22 VLP was mutated with cysteine (S133C or K118C, respectively) to conjugate 
cargo molecules through thiol-maleimide conjugation 18, 36. We used two affibody molecules which 
selectively bind to EGFR and HER2 (EGFRAfb and HER2Afb, respectively) 37-38 as targeting ligands, 
because breast cancer cells usually overexpress EGFR, HER2, or both on their surfaces and they are 
well-known tumor biomarkers for diagnosis and therapeutics 39. SpyCatcher was genetically fused to 
the N-termini of EGFRAfb and HER2Afb with an extra linker to produce SC-EGFRAfb and SC-
HER2Afb, respectively 22, 24. P22 VLP-ST were overexpressed in E. coli, purified by sucrose gradient 
centrifugation, and heated at 75°C for 15 min to remove scaffold proteins and form a wiffle ball 
structure, denoted P22 WB-ST 40. P22 WB-ST have genome- and scaffolding protein-free hollow 
architectures, with sufficient space for accommodating small chemotherapeutic agents and/or 
diagnostic probes within their cavity 36. The twelve 10-nm pores of P22 WB-ST could be used as 
portals for the entry and exit of even larger molecular species 41 and the C-terminal end of capsid 
protein is surely exposed to the surface in the form of P22 WB 20, 35. Formation of the wiffle ball 
structure was confirmed by removing scaffold proteins using SDS-PAGE and assessing the mobility 
shift on native agarose gels (Figure 3.1A and B). The hydrodynamic diameter, as determined by 
dynamic light scattering (DLS), was slightly increased (Figure 3.1C) when there was an intact cage 
architecture, as confirmed by transmission electron microscopy (TEM) (Figure 3.1D). Independently, 
SC-Afb (SC-EGFRAfb and SC-HER2Afb) were overexpressed in E. coli and purified with Ni-NTA-
based immobilized metal affinity chromatography (Ni-NTA-agarose columns). Using purified SC-Afb 
and P22 WB-ST, we first investigated the number of affibody molecules which could be loaded on a 
P22 WB-ST without altering the protein cage nanoparticle architecture. We fixed the amount of P22 
WB-ST and varied the input amounts of SC-Afb (Figure 3.2A and B). The degree of isopeptide 
formation between the P22 WB-ST subunits and SC-Afb increased as the input ratio of SC-Afb to P22 
WB-ST subunits increased, up to 0.4, and reaction mixtures started to aggregate at ratios higher than 
0.5. Although there is no atomic resolution structure of P22 VLP, we hypothesize that the C-termini of 
P22 WB-ST subunits may have clustered together as the amounts of attached SC-Afb increased and 
excess amounts of attached SC-Afb resulted in aggregation of P22 VLP conjugates similar to those 
observed in sortase-mediated conjugations 20. Densitometric analyses indicated that approximately 
150 copies of affibody molecules were attached to 1 P22 WB-ST with a 0.4 SC-Afb input ratio on 
average, a result which matches well with the number calculated: 144 copies of affibody molecules 
(0.4 x 360 subunit/P22 WB-ST) (Figure 3.3A). We therefore prepared P22 WB-ST/SC-Afb using this 
ratio, to maximize the number of targeting ligands per particle, while minimizing particle aggregation.  
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Figure 3.1 Characterization of wiffle ball form of P22 VLP-ST (P22 WB-ST). (a) SDS-PAGE 
analyses of P22 VLP-ST and P22 WB-ST. (b) Native agarose gel electrophoresis analyses of P22 
VLP-ST and P22 WB-ST. (c) Dynamic light scattering (DLS) analyses of P22 VLP-ST and P22 WB-
ST. (d) Transmission electron microscopy (TEM) images of P22in WB-ST and P22ex WB-ST. 
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Figure 3.2 SDS-PAGE analyses of reaction results of P22 VLP-ST and SC-Afb at various input ratio 
and reaction times. Reaction resultants of (a) P22in WB-ST with SC-Afb and (b) P22ex WB-ST with 
SCAfb at various input ratio (1:0.4, 1:0.5, 1:0.8 and 1:1 molar ratios). Reaction results of (c) P22in 
WB-ST with SC-EGFRAfb and (d) P22in WB-ST with SC-HER2Afb at various reaction times as 
indicated. 
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Figure 3.3 Characterization of P22in WB‐Afb. (A) SDS‐PAGE analyses of reaction results of 
P22in WB‐ST and SC‐EGFRAfb or SC‐HER2Afb at an optimal input ratio. (B) Dynamic light 
scattering (DLS) analyses of the reaction results of P22in WB‐ST and SC‐EGFRAfb or SC‐HER2Afb 
and P22in WB‐ST only. Transmission electron microscopy images of P22in WB‐ST/SC‐EGFRAfb (C) 
and P22in WB‐ST/SC‐HER2Afb (D) stained with 2% uranyl acetate 
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Isopeptide bond formation between P22 WB-ST and SC-Afb was almost complete within 30 min 
(Figure 3.2C and D), and there was no noticeable amount of aggregation after an overnight reaction. 
The average diameter of P22 WB-ST/SC-Afb determined by DLS was 79 ± 2 nm, slightly larger than 
that of P22 WB-ST (70 ± 2 nm), indicating that SC-Afb are covalently attached to the exterior 
surfaces of P22 WB-ST (Figure 3.3B). TEM images of SC-Afb-treated P22 WB-ST showed intact 
cage architectures, although we could not clearly observe extra density on their surfaces (Figure 3.3C 
and D). To test whether each P22 WB-ST/SC-Afb could selectively recognize its target cells and bind 
tightly to them, we labeled P22 WB-ST/SC-Afb (P22 WB-ST/SC-EGFRAfb or P22 WB-ST/SC-
HER2Afb) with fluorescein-5-maleimide (F5M) via a thiol-maleimide coupling reaction. P22 WB-
ST/SC-Afb has one cysteine per subunit either on the interior (P22in WB-ST) or the exterior surface 
(P22ex WB-ST) of P22 WB-ST. We first tested P22in WB-ST, because interior fluorescein labeling 
would not interrupt the binding capacity of the affibody molecules displayed on the exterior surfaces 
of the P22 WB-ST/SC-Afb. We determined the degree of fluorescein conjugation to P22in WB-ST/SC-
Afb by measuring absorbance at 488 and 280 nm, representing the amounts of fluorescein and P22in 
WB-ST subunit concentrations, respectively. Almost every subunit of P22in WB-ST was labeled with 
one fluorescein (fP22in WB-ST, Figure 3.4). Subsequently, SC-EGFRAfb and SC-HER2Afb were 
covalently ligated to fP22in WB-ST by simply mixing them at the previously determined optimized 
reaction ratio (fP22in WB-ST subunit/SC-Afb = 1:0.4). 
MDA-MB-468 cells, known to overexpress EGFR on their membranes, and SK-BR-3 cells, known 
to overexpress HER2 on their membranes, were prepared and treated with fP22in WB-ST/SC-
EGFRAfb and fP22in WB-ST/SC-HER2Afb, respectively. The fluorescent microscopy images showed 
that fP22in WB-ST/SC-EGFRAfb and P22in WB-ST/SC-HER2Afb bound efficiently to their 
corresponding MDA-MB-468 and SK-BR-3 cells, whereas cells treated with fP22in WB-ST did not 
exhibit any fluorescent signal (Figure 3.5A and B). MCF-7 and MCF-10A cells, which do not 
overexpress EGFR and HER2 respectively, were also treated with fP22in WB-ST/SC-EGFRAfb and 
fP22in WB-ST/SC-HER2Afb, respectively, as negative controls and did not show any fluorescent 
signals (Figure 3.6A and B). These data indicated that P22in WB-ST/SC-Afb efficiently and 
selectively bound to their target receptor molecules allowing the detection of specific target cells, with 
minimal non-specific binding. We also used P22ex WB-ST instead of P22in WB-ST and obtained 
almost identical results (Figure 3.7 and Figure 3.8) demonstrating that the exterior chemical 
conjugations of fluorescein do not interfere with targeting ligand ligations or target cell bindings. 
To assess the potential of P22 WB-ST/SC-Afb as modular drug carriers, we chemically conjugated 
6-maleimidocaproyl hydrazine, a prodrug of doxorubicin (AlDox) to P22in WB-ST instead of to F5M, 
as a representative anticancer drug. AlDox is a doxorubicin prodrug that contains a maleimide moiety 
attached via an acid-sensitive hydrazine linker 42. When AlDox is trapped in acidic conditions, such as 
those in the endosome, lysosomes, and tumor environments, doxorubicin (Dox) is released through  
63 
 
 
Figure 3.4 Concentration dependent absorbance profiles of fluorescein-5-maleimide (a) and 
Aldoxorubicin (b). (c) Binding ratio of F5M and AlDox to P22 VLP-ST based on absorbance profiles. 
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Figure 3.5 Fluorescent microscopic images of MDA‐MB‐468 cells (a) and SK‐BR‐3 cells (b) treated 
with fP22in WB‐ST/SC‐EGFRAfb and fP22in WB‐ST/SC‐HER2Afb, respectively. fP22in WB‐ST was 
also independently treated (lower panels). Fluorescent microscopic images of MDA‐MB‐468 cells (c) 
and SK‐BR‐3 cells (d) treated with AlDox‐P22in WB‐ST/SC‐EGFRAfb and AlDox‐P22in WB‐ST/SC‐
HER2Afb, respectively. AlDox‐P22in WB‐ST was also independently treated (lower panels). Treated 
samples and cells are indicated on the left and right of the image panels, respectively. Nuclei are 
stained by DAPI (left panels, blue), fluorescein and AlDox are visualized in green and red, 
respectively (upper panels). Scale bar = 20 μm 
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Figure 3.6 Fluorescent microscopic images of MCF-7 cells (a) and MCF-10A cells (b) treated with 
fP22in WB-ST/SC-EGFRAfb and fP22in WB-ST/SC-HER2Afb, respectively. fP22in WB-ST was 
also independently treated (lower panels). Fluorescent microscopic images of MCF-7 cells (c) and 
MCF10A cells (d) treated with AlDox-P22in WB-ST/SC-EGFRAfb and AlDox-P22In WB-ST/SC-
HER2Afb, respectively. AlDox-P22in WB-ST was also independently treated (lower panels). Treated 
samples and cells are indicated on the left and right of the image panels, respectively. Nuclei are 
stained by DAPI (left panels, blue), fluorescein and AlDox are visualized in green and red, 
respectively (upper panels). Scale bar = 20 μm  
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Figure 3.7 Fluorescent microscopic images of MDA-MB-468 cells (a) and SK-BR-3 cells (b) treated 
with fP22ex WB-ST/SC-EGFRAfb and fP22ex WB-ST/SC-HER2Afb, respectively. fP22ex WB-ST 
was also independently treated (lower panels). Fluorescent microscopic images of MDA-MB-468 
cells (c) and SK-BR-3 cells (d) treated with AlDox-P22ex WB-ST/SC-EGFRAfb and AlDox-P22ex 
WB-ST/SCHER2Afb, respectively. AlDox-P22ex WB-ST was also independently treated (lower 
panels). Treated samples and cells are indicated on the left and right of the image panels, respectively. 
Nuclei are stained by DAPI (left panels, blue), fluorescein and AlDox are visualized in green and red, 
respectively (upper panels). Scale bar = 20 μm  
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Figure 3.8 Fluorescent microscopic images of MCF-7 cells (a) and MCF-10A cells (b) treated with 
fP22ex WB-ST/SC-EGFRAfb and fP22ex WB-ST/SC-HER2Afb, respectively. fP22ex WB-ST was 
also independently treated (lower panels). Fluorescent microscopic images of MCF-7 cells (c) and 
MCF10A cells (d) treated with AlDox-P22ex WB-ST/SC-EGFRAfb and AlDox-P22ex WB-ST/SC-
HER2Afb, respectively. AlDox-P22ex WB-ST was also independently treated (lower panels). Treated 
samples and cells are indicated on the left and right of the image panels, respectively. Nuclei are 
stained by DAPI (left panels, blue), fluorescein and AlDox are visualized in green and red, 
respectively (upper panels). Scale bar = 20 μm 
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low pH-induced cleavage of the hydrazine linkage and the released Dox can enter the nucleus, 
disrupting the genomic DNA, DNA repair systems, or both 43-44. As with F5M, we conjugated P22in 
WB-ST with AlDox and subsequently ligated them with SC-Afb (AlDox-P22in WB-ST/SC-EGFRAfb 
or AlDox-P22in WB-ST/SC-HER2Afb). Almost every subunit of P22in WB-ST was conjugated with 
AlDox (Figure 3.4), and their architecture was not altered. MDA-MB-468 and SK-BR-3 cells were 
treated with AlDox-P22in WB-ST/SC-EGFRAfb and AlDox-P22in WB-ST/SC-HER2Afb, respectively. 
Red fluorescent signals from the released Dox appeared in the nuclei of the cells treated with AlDox-
P22in WB-ST/SC-EGFRAfb or AlDox-P22in WB-ST/SC-HER2Afb but not with AlDox-P22in WB-ST 
(Figure 3.5C and D). These results indicated that AlDox-P22in WB-ST/SC-EGFRAfb and AlDox-
P22in WB-ST/SC-HER2Afb selectively bound to EGFR and HER2 on the surface of MDA-MB-468 
and SK-BR-3 cells, respectively, resulting in receptor-mediated endocytosis and subsequent cleavage 
of the hydrazine linkage in endosomes. Dox released from endosomes enters the nuclei and kills the 
cells. MCF-7 and MCF-10A cells were also treated with AlDox-P22in WB-ST/SC-EGFRAfb and 
AlDox-P22in WB-ST/SC-HER2Afb, and no Dox signal was detected (Figure 3.6C and D). These data 
suggested that AlDox-P22in WB-ST/SC-Afb do not bind to any cells non-specifically, consistent with 
the observations made using fluorescent microscopy, thus avoiding non-specific delivery of drugs to 
non-target cells. We performed the same experiments with AlDox-P22ex WB-ST/SC-EGFRAfb and 
AlDox-P22ex WB-ST/SC-HER2Afb and obtained almost identical results (Figure 3.7 and Figure 3.8). 
These data indicated that targeting, imaging, and therapeutic molecules could be simultaneously 
incorporated into P22 WB-ST and the system can deliver cargo molecules to target sites selectively 
and precisely. 
To evaluate the cytotoxicity of Dox delivered by P22 WB-ST/SC-Afb, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide (MTT) cell viability assays were performed. MDA-MB-468 and 
SK-BR-3 cells were treated with AlDox-P22in WB-ST/SC-EGFRAfb and AlDox-P22in WB-ST/SC-
HER2Afb, respectively, for 3 h. Free Dox was used as a positive control and P22in WB-ST/SC-Afb 
without AlDox as a negative control. Following incubation, the cells were washed with growth media 
and cultured for an additional 48 h before cell viability was measured with MTT assays. The cytotoxic 
effects of both AlDox-P22in WB-ST/SC-Afb and free Dox on MDA-MB-468 or SK-BR-3 cells 
increased in a dose-dependent manner (Figure 3.9A and B). AlDox-P22in WB-ST/SC-EGFRAfb had 
slightly higher cytotoxicity to MDA-MB-468 cells than Dox-treated cells. These results indicated that 
active targeting of P22 WB-ST/SC-EGFRAfb delivered Dox more effectively than the diffusion of 
free Dox. However, in the case of SK-BR-3 cells, Aldox-P22 WB-ST/SC-HER2Afb exhibited similar 
cytotoxicity to that of free Dox. One of the main advantages of targeted delivery should be a reduction 
in side effects, achieved by minimizing off-target effects. To test for off-target effects of AlDox-P22in 
WB-ST/SC-Afb, MCF-7 and MCF-10A cells were treated with AlDox-P22in WB-ST/SC-EGFRAfb 
and AlDox-P22in WB-ST/SC-HER2Afb, respectively, and free Dox (Figure 3.9C and D). 
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Approximately 50%–60% of MCF-7 and MCF-10A cells were killed with 20 μM of free Dox, a 
similar proportion to those treated with MDA-MB 468 and SK-BR3, whereas only basal levels of 
MCF-7 and MCF-10A cells were killed by AlDox-P22in WB-ST/SC-EGFRAfb and AlDox-P22in WB-
ST/SC-HER2Afb. These results indicated that P22in WB-ST/SC-Afb could be used as a drug delivery 
vehicle in target cells, minimizing the off-target effects of commonly used prodrugs. We also 
evaluated the cytotoxicity of AlDox-P22ex WB-ST/SC-Afb and obtained almost identical results 
(Figure 3.10). These results indicated that attachment of cargo molecules to the exterior surface of 
P22 WB-ST/SC-Afb does not affect their targeting capability and that both the interior and exterior 
surfaces of P22 WB-ST/SC-Afb could be utilized for multiple cargo loading sites. 
  
70 
 
 
Figure 3.9 MTT cell viability assay. (a) Dose‐dependent cytotoxic effects of AlDox‐P22in WB‐
ST/SC‐EGFRAfb (black), free Dox (gray), and AlDox‐P22in WB‐ST (white) on MDA‐MB‐468 cells. 
(b) Dose‐dependent cytotoxic effects of AlDox‐P22in WB‐ST/SC‐HER2Afb (black), free Dox (gray), 
and AlDox‐P22in WB‐ST (white) on SK‐BR‐3 cells. (c) Dose‐dependent cytotoxic effects of AlDox‐
P22in WB‐ST/SC‐EGFRAfb (black), free Dox (gray), and AlDox‐P22in WB‐ST (white) on MCF‐7 
cells. (d) Dose‐dependent cytotoxic effects of AlDox‐P22in WB‐ST/SC‐HER2Afb (black), free Dox 
(gray), and AlDox‐P22in WB‐ST (white) on MCF‐10A cells. Five independent experiments were 
performed, and error bars are indicated 
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Figure 3.10 MTT cell viability assay. (a) Dose-dependent cytotoxic effects of AlDox-P22ex WB-
ST/SCEGFRAfb (black), free Dox (grey), and AlDox-P22ex WB-ST (white) on MDA-MB 468 cells. 
(b) Dosedependent cytotoxic effect of AlDox-P22ex WB-ST/SC-HER2Afb (black), free Dox (grey), 
and AlDoxP22ex WB-ST (white) on SK-BR 3 cells. (c) Dose-dependent cytotoxic effects of AlDox-
P22ex WBST/SC-EGFRAfb (black), free Dox (grey), and AlDox-P22ex WB-ST (white) on MCF-7 
cells. (d) Dosedependent cytotoxic effects of AlDox-P22ex WB-ST/SC-HER2Afb (black), free Dox 
(grey), and AlDox-P22ex WB-ST (white) on MCF-10A cells. Five independent experiments were 
performed, and error bars are indicated 
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3.4 Conclusions 
 
In this study, we developed P22 VLP‐based target‐tunable delivery nanoplatforms that can deliver 
fluorescent dyes or anticancer drugs, such as Dox to target cells with precision. ST‐inserted P22 WB 
and SC‐fused EGFR and HER2 affibody molecules were independently prepared and were covalently 
ligated according to their target cells. A fluorescent dye, fluorescein, and the prodrug AlDox were 
chemically conjugated to P22 WB‐ST/SC‐Afb on either interior or exterior surfaces and successfully 
delivered to the cytosol and nuclei of their target cells, resulting in effective cell imaging and selective 
target cell killing. The AlDox‐P22 WB‐ST/SC‐Afb showed high specificity toward their target cells, 
minimizing nonspecific delivery of toxic drugs to nontargeted cells. P22 VLP had a robust genome‐
free hollow structure with high symmetry, providing sufficient space for loading therapeutic cargoes 
and diagnostic probes on the interior or exterior surfaces, and the SpyTag/SpyCatcher ligation system 
allowed us to covalently display two different large targeting ligands on P22 VLP. The approach we 
describe here can be applied to multifunctional delivery by the conjugation of two or more functional 
proteins, as well as affibody molecules. We anticipate that this platform could display proteins even 
larger than affibody molecules by controlling the molar ratio with respect to P22 VLP. In addition to 
the exterior surface with target‐specific ligands, the interior cavity of P22 VLP can be used for 
encapsulating functional proteins, such as enzymes and therapeutic proteins. The dual modification 
approach may provide new opportunities for developing biomolecule‐based target‐specific functional 
protein delivery systems. 
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Chapter 4. Cloaking nanoparticles with protein corona shield for targeted 
drug delivery 
 
 
4.1 Introduction 
 
The application of nanoparticles is promising for the development of imaging and therapeutic 
agents through improved biodistribution and controlled drug release1-3. The rationale behind using 
nanoparticles is that those with diameters of <200 nm extravasate from the leaky tumor blood vessels 
are retained in the tumor due to the “enhanced permeability and retention” (EPR) effect4. Although 
few nanoparticle formulations (e.g., Abraxane and Doxil) are available in the market, the ubiquitous 
targeting approach suffers from several limitations including rapid clearance by the mononuclear 
phagocyte system (MPS) and low uptake into target tumors5-6. To improve the targeting ability, along 
with the EPR effect, an active targeting approach has been attempted by coating the particle surface 
with antibodies, proteins, or peptides that bind to receptors that are typically overexpressed on cancer 
cells7. However, recent reports have revealed only a modest increase in tumor targeting when this 
approach is applied; moreover, the addition of targeting ligands increased the clearance of 
nanoparticles by MPS, indicating that no definitive conclusion has been reached regarding the 
therapeutic efficacy of this technique8-9. In principle, when exposed to physiological environments, 
the nanoparticle surface is covered by various biomolecules to lower the surface energy by a 
combination of entropy-driven water molecule displacement, particle surface charge compensation, 
and screening of hydrophobic parts10-12. Biomolecule adsorption results in the formation of a layer, 
called a protein corona, and significantly changes the original molecular identity of the nanoparticle13. 
The formation of a protein corona on the nanoparticle surface can be regulated by modifying the 
nanoparticle surface with zwitterions, polyethylene glycol (PEG), carbohydrate moieties, and 
dysopsonic proteins, which can enhance the colloidal stability and prolong the circulation time in 
blood by enabling escape from MPS clearance14-17. However, these strategies are still limited at 
conferring targeting specificity since an additional targeting ligand increases the propensity for 
protein corona formation to mask the targeting ability and inhibit the biological effects of 
nanoparticles18-24. This can explain why many nanoparticles with active targeting systems have failed 
in clinical trials25. Therefore, to design nanoparticle-based therapeutic agents, there is a considerable 
need to regulate protein corona formation on nanoparticles26-28 and to obtain a deeper understanding of 
the molecular mechanism involved in regulating nanoparticle–biological interactions. Here, we 
present a targeting system in which nanoparticles are supramolecularly pre-coated with a protein 
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corona shield (PCS) that reduce serum protein absorption while retaining targeting specificity 
(Scheme 4.1). 
 
Scheme 4.1 Protein corona shield nanoparticle (PCSN). We introduce the protein corona shield (PCS) 
concept for an efficient target drug delivery system. Generally, nanoparticle drug carriers with a target 
ligand lose their targeting ability on being coated by blood proteins in a biological environment. 
However, the PCS system can inhibit blood protein adsorption to maintain the targeting ability and 
avoid unwanted clearance by the mononuclear phagocyte system. 
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4.2 Materials and Methods 
 
Materials 
Cetyltrimethylammonium bromide (CTAB), Pluronic® F-127 (EO106PO70EO106), tetraethyl 
orthosilicate (TEOS; 98%, reagent grade), fluorescein isothiocyanate, toluene (99.9% anhydrous), 
pyridine, dimethylformamide (HPLC grade), disuccinimidyl suberate, and dimethyl sulfoxide were 
purchased from Sigma-Aldrich (Yongin S. Korea). 3-(Trimethoxysilyl) propyl acrylate, (3-
aminopropyl) trimethoxysilane, succinic acid anhydride, and L-glutathione reduced (>98%) were 
purchased from Tokyo Chemical Industries (TCI) (Tokyo, Japan). 1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI), DiD were purchased from Thermo Fisher. CPT was 
obtained from Ontario Chemicals Inc. (Ontario, Canada). Doxorubicin (Dox) was obtained from 
Acorn PharmaTech (Redwood City, CA, USA). Anhydrous ethanol, sodium hydroxide (NaOH; 99%), 
and ammonium hydroxide (29 wt%) were purchased from Samchun Chemical. All chemicals were 
used as received without further purification. Deionized (DI) water was produced by the Millipore 
Milli-Q System (18.2 MΩ cm). Isopropyl β-D-1-thiogalactopyranoside was purchased from Bio Basic. 
Lysozyme was purchased from Sigma-Aldrich. PBS (10×) without calcium or magnesium was 
purchased from Lonza. One milliliter HisTrap FF column was purchased from GE HealthCare. 
DuoflowTM chromatography system was purchased from Bio-rad. BCA assay was purchased from 
Thermo Fisher. MassPREP microdesalting column and Xevo G2 TOF MS were purchased from 
Waters. All the other chemicals were purchased from Bioshop. SK-BR-3 cells were purchased from 
the Korean cell line bank (KCLB catalog No. 30030). MDA-MB-468 cells were purchased from the 
Amerian Type Culuture Collection (ATCC Catalog No. HTB-132). All cell culture reagents and 
medium were from Life Technologies (S. Korea) and FBS was purchased from Gold Standard (USA). 
The graphics found in the figures were created by a co-author. 
 
Cell culture 
Human breast cancer cells derived from the metastatic sites MDA-MB468 and SK-BR3 were 
obtained. Normal macrophage cell lines RAW264.7 and HeK293T were obtained as a gift from Prof. 
Hyun Woo Rhee at UNIST. SK-BR3 and RAW264.7 cells were cultured in DMEM medium 
(Invitrogen, S. Korea), and MDA-MB468 in Leibovitz-L-15 media (Invitrogen, S. Korea) was 
supplemented with 10% FBS, 100 µg/mL streptomycin, and 100 U/mL penicillin at 37 °C in a 
humidified incubator containing 5% CO2 and 95% air. The medium was replenished every other day, 
and the cells were subcultured after reaching >85% confluence. 
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Cell viability analysis 
The in vitro cell viabilities of various formulations against SK-BR3 and MDA-MB468 cells were 
determined by performing the Alamar blue dye assay (Invitrogen, Korea). Briefly, SK-BR3 and 
MDA-MB468 cells were cultured in 96-well (Thermo Scientific Inc. Korea) micro-titer plates at a 
density of 5 × 103 cells/well and then allowed to settle for 24 h under incubation at 37 °C, 95% air, and 
5% CO2. Then, the grown cells were treated with different concentrations of pristine MSN, GSH-
MSN, and EGFR- and Her2-Afb-modified MSN (10 µg/mL to 1 mg/mL) in both cell lines and 
analyzed after 24-h incubation at an excitation wavelength of 565 nm and an emission wavelength of 
590 nm using a fluorescence plate reader (Tecan Infinite Series, Germany). Similarly, CPT-loaded 
EGFR and Her2 PCSN along with free-CPT were analyzed using similar methods (0.01, 0.1, 0.25, 0.5, 
1, 2.5, and 5 µg/mL of CPT). 
 
Cellular uptake analysis 
The cellular uptake of CPT-loaded nanoparticles was investigated with confocal microscopic and 
flow cytometric analyses. HeK293T, MDA-MB468, and SK-BR3 cells were seeded into two-well 
chambers with a cover glass (Lab Tek II; Thermo Scientific) at a seeding density of 2 × 105 cells/well. 
After a 24-h incubation, the cells were treated with CPT-loaded PCSN at a final concentration of CPT 
of 10 µg/mL at different time points and analyzed with confocal microscopy. Similarly, the cells were 
stained with lysotracker green (Lysotracker Green FM DND-26; Invitrogen) to check the 
colocalization with the CPT-loaded MSN. To evaluate the drug release from MSN, the FITC-
conjugated MSNs were loaded with CPT and the releases at varying time points (2, 1, and 16 h) were 
checked. To evaluate cellular uptake, DiI-loaded MSNs were used for flow cytometric analysis. 
HeK293T, SK-BR3, and MDA-MB468 cells were seeded into six-well plates at a density of 
1 × 106 cells per well and incubated in a complete medium for 24 h at 37 °C, 95% air, and 5% CO2. 
The concentration of DiI nanoparticles was equivalent to a DiI dosage of 0.20 µg/mL. After the 
stipulated period of 4 and 6 h of incubation, the different treatment cells were trypsinized, harvested, 
rinsed with PBS, resuspended, and subjected to flow cytometry assay using BD-FACS Caliber. All 
experiments detected ≥10,000 cells, and the data were analyzed using the FlowJo software. 
 
Endocytic pathway analysis 
To check the endocytosis-mediated uptake, SK-BR3 cells were seeded into four-well chambers 
with cover glass and pretreated with different inhibitors, including sucrose (clathrin-mediated uptake, 
400 nM), methyl-beta cyclodextrin (caveolae-mediated uptake), and amilorin (macropinocytosis), in a 
serum-free DMEM for 1 h and replaced with fresh media. Afterward, DiI-loaded PCSNs were added 
to the medium for another 1 h of incubation. Then, the cells were analyzed with a confocal 
microscope (Olympus FV1000) connected to a CO2 incubator. 
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Animals and tumor models 
Female nude mice (18 ± 2 g, 6 weeks of age) were fed under the condition of 22 ± 2 °C and 55 ± 5% 
humidity, with free access to food and water. All animal experiments were approved by the 
Institutional Animal Care and Use Committee at Ulsan National Institute of Science and Technology 
and conducted in compliance with the guidelines (UNIST-IACUC-17-29). To set up the tumor 
xenograft model, mice were subcutaneously inoculated in the right lower leg with 1 × 106 human 
breast cancer SK-BR3 cells. Tumor volume (V) was determined by the following 
equation: V = L × W2/2, where L and W are the length and width of the tumor, respectively. SK-BR3 
tumor-bearing mice were used in the experiments when the tumor volumes reached approximately 
100 mm3. 
 
In vivo and ex vivo fluorescence imaging 
To evaluate the biodistribution of GSH-MSN, PEG-MSN, and PCSN loaded with a lipophillic dye, 
DiD (at 10 wt% loading capacity) was intravenously injected (0.1 mg/mL) into SK-BR3 tumor-
bearing nude mice (7 mice/group). Then, the mice were anesthetized and imaged using an in vivo 
imaging system (Bruker Xtreme) with an excitation wavelength of 630 nm and emission wavelength 
of 700 nm. In vivo images were taken at 0.5, 1, 2, 4, 8, 10, 12, 24, 32, and 48 h. Then, the mice were 
killed to separate the organs and tumors for ex vivo imaging to determine the biodistribution pattern 
of DiD-loaded nanocarriers. 
 
In vivo tumor inhibition analysis 
Female nude mice (average weight 18.5 ± 2 g) were obtained from Orientbio, Korea, for the in vivo 
studies. All protocols for the in vivo experiments were approved by the UNIST-IACUC animal ethics 
approval committee. SK-BR3 tumor-bearing mice were used to carry out experiments when the tumor 
volumes reached approximately 300 mm3. The tumor-bearing nude mice were randomly divided into 
five groups (6 mice per group). PBS, free-CPT, PCSN, CPT-loaded PEG-MSN, and CPT-loaded 
PCSN were intravenously injected into mice every 3 days seven times. CPT dosage was 1.5 mg/kg 
body weight. The first day of treatment was defined as day 0. The body weight and tumor size were 
recorded every 3 days, and the survival of mice was monitored throughout the experiment. The 
concentrations used for the groups treated with PCSN were the same as that of CPT-PCSN. After 
treatment for 21 days, related mice were killed, and the tumor tissues were removed from the bodies 
to investigate the morphology and use for further studies. 
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Histochemical analysis 
At day 22, one mouse in each group was sacrificed to separate the tumors, and the mice were then 
fixed in 4% formaldehyde solution in PBS. For histochemical staining, the fixed tumors were 
dehydrated by gradient ethanol washing and embedded in paraffin blocks, sectioned, and stained with 
H&E staining. 
 
Statistical analysis 
All data were reported as means ± standard deviations (SDs). Microsoft Excel software was used to 
calculate P-values for unpaired t-tests. Statistical significance was determined by using Student’s t-
test and one-way analysis of variance, and P-values of <0.05 were considered to be indicative of 
statistical significance. 
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4.3 Results and discussion 
 
To develop PCS on nanoparticles, we use a recombinant fusion protein, GST-HER2-Afb, in which 
HER2-binding affibody (Afb) is genetically combined with a glutathione-S-transferase (GST)29, a 
well-known fusion tag protein, with an extra linker (GGGLVPRGSGGGCGGGGTGGGSGGG). The 
preparation of GST-HER2-Afb (molecular weight: 36.3 kDa, >99.0% purity) is confirmed by 
electrospray ionization time-of-flight mass spectrometry (Figure 4.1A) and sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 4.2A). The surface charge of the GST-
HER2-Afb at physiological pH is approximately −5.25 mV, which is similar to that of GST 
(−6.29 mV) (Figure 4.1B). The intact binding ability of GST-HER2-Afb is confirmed by monitoring 
its interactions with the targeting receptor HER2/ErbB2 in real time using a quartz crystal 
microbalance (Figure 4.2B) and the cellular uptake of the fluorescein-labeled GST-HER2-Afb to the 
HER2-receptor-overexpressing cell line (SK-BR3) (Figure 4.1D). These results indicate that the 
recombinant fusion protein with the linker, GST-HER2-Afb, exhibit the ability to bind to the 
complementary receptor. Furthermore, the toxicity test confirms its biocompatibility, indicating that 
GST-HER2 itself is not toxic up to 10 μM (Figure 4.2C). Next, PCS nanoparticles (PCSNs) were 
constructed by supramolecularly attaching GST-HER2-Afb to mesoporous silica nanoparticle (MSN), 
for which cargo molecules can be loaded in the interior30. First, 3-(trimethoxysilyl) propyl acrylate 
was modified on MSN (mean diameter: 140 ± 10 nm in a dynamic light scattering (DLS), surface area: 
1190 m2/g, pore volume: 1.10 cm3/g, mean pore size: 2.68 nm; Figure 4.3; Table 4.1) and glutathione 
(GSH) was further attached using thiol-ene click chemistry, which was confirmed by FT-IR analysis 
(Figure 4.3D). The hydrodynamic radius of the GSH-modified MSN (GSH-MSN) was ~140 ± 20 nm, 
as confirmed by DLS experiment, and the diameter of GSH-MSN observed from transmission 
electron microscopic (TEM) images was ~90 ± 10 nm (Figure 4.1E). GSH modification decreased the 
surface area (540 m2/g), pore volume (0.5 cm3/g), and mean pore size (2.04 nm) (Figure 4.3B and C; 
Table 4.1). Nevertheless, the GSH-MSN showed a decent cargo loading capacity of 52%, 65%, 11%, 
and 5% for doxorubicin (DOX), camptothecin (CPT), DiIC18 (DiI), and DiD, respectively (Figure 4.4; 
Table 4.2). The GSH-MSN was then coated with GST-HER2-Afb to give the PCSN through the 
supramolecular interaction at the GSH-binding site. The attachment of GST-HER2 on GSH-MSN was 
confirmed by measuring the surface charge, which changed from −40 mV (GSH-MSN) to −5.3 mV 
(PCSN) (Figure 4.1B). The DLS experiment indicated an increase in the hydrodynamic radius of 
PCSN (~270 ± 20 nm) compared with that of GSH-MSN (~140 ± 20 nm) (Figure 4.5), and the TEM 
image analysis further confirmed the protein-coating layer (Figure 4.1E). The maximum number of 
GST-HER2-Afb attached on GSH-MSN was 270 μg/mg, which was confirmed by BCA assay (Figure 
4.5B). No significant aggregation of PCSNs was observed in the DLS analysis up to 2 weeks at 4 °C 
(Figure 4.1C). Next, we investigated interactions occurring at the interfaces between serum proteins 
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and PCSNs. Control particles, GSH-MSN, and PEG-modified MSN (PEG-MSN)31 were used to study 
the effects of GST-HER2-Afb pre-coating on particles. We first incubated PCSN, PEG-MSN, and 
GSH-MSN with 55% fetal bovine serum (FBS) for 1, 2, and 4 h and isolated the serum proteins that 
adsorbed to them by centrifugation to completely remove unbound proteins. The molecular 
composition of the adsorbed serum proteins was measured by denaturing SDS-PAGE and the protein 
density was plotted (Figure 4.6A and B). The protein profiles observed for PEG-MSN and GSH-MSN 
were fairly similar, but the intensities of the bands for PCSN were significantly reduced (~15-fold 
lower intensity than for GSH-MSN for the case of 1 h of incubation), indicating that the GST-HER2-
Afb pre-coating on PCSN could reduce the interactions with serum proteins. To further confirm the 
particle–protein interactions, the physical characterizations were also investigated by using DLS, zeta, 
and PDI (Figure 4.7). The treatment of 55% serum on GSH-MSN and PEG-MSN increased its 
hydrodynamic radius and changed its surface charge while PCSN showed no significant changes, 
confirming the decreased PCSN–serum protein interactions. We then investigated the composition of 
serum proteins adsorbed on each particle using shotgun proteomics [liquid chromatography tandem 
mass spectrometry (LC-MS/MS)]. A total of 183 proteins were identified and the 78 most abundant 
proteins (at levels >0.01% w/w) were selected and divided into three groups based on the correlation 
in their relative abundances on each particle (Group 1: GSH-MSN > PEG-MSN > PCSN, Group 2: 
GSH-MSN ≈ PEG-MSN > PCSN, Group 3: GSH ≈ PEG-MSN ≈ PCSN, as shown in Figure 4.6C), 
which exhibited the lowest tendency to be adsorbed on PCSN. The proteins were further classified 
according to the weight, isoelectric point, and serum protein classification (expressed as a percentage 
of each protein in Figure 4.6D, middle). The proteins adsorbed on PCSN were composed of lower-
molecular-weight proteins (20–60 kDa) (Figure 4.6D, left) and included an abundance of proteins 
with pI of approximately 7–8 compared with the proteins adsorbed on GSH-MSN and PEG-MSN 
(Figure 4.6D, right). Moreover, the amount of immune response involving proteins, complement, and 
coagulation proteins adsorbed on PCSN was significantly lower than those on GSH-MSN and PEG-
MSN, suggesting that PCSN can increase their circulation time in the blood by decreasing the uptake 
from the immune system20. It is also noted that the relative quantity of apolipoproteins among serum 
proteins absorbed on PCSN increased with respect to GSH-MSN and to PEG-MSN (Figure 4.6D, 
middle). Considering that apolipoproteins on nanoparticle play an important role in association with 
cellular uptake to target cells32-34, targeting capability of PCSN partly could be linked with some 
serum proteins recruited at the surface of PCSN. To understand the interactions between PCS and 
external biological components, we investigated the molecular mechanisms of the interactions 
associated with the conformational change of GST-HER2-Afb. When non-covalently adsorbed on 
nanoparticles with precisely designed supramolecular interaction, specific domains of proteins can 
interact with the surface of nanoparticles in thermodynamically favorable manners, leading to the 
colloidal stabilization and dysopsonization of particles in a physiological environment35-36. On the 
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other hand, covalent attachment of their counterparts on particles significantly changes their 
conformations and particle surface properties (e.g., hydrophobicity and charge density), inducing 
potential detrimental interactions with external biomolecules, rather than stabilizing them13, 19, 37. 
Therefore, assuming that the orientation and conformational change of proteins adsorbed on particles 
are subject to interaction with serum proteins, the effects of chemical modification of GST-HER2-Afb 
on biological consequences were investigated. First, PCSNs having randomly orientated GST-HER2-
Afb [PCSN(R)s] were prepared by chemically conjugating GST-HER2-Afb to succinimidyl-modified 
MSN via amide formation with amine groups on the protein surface (Figure 4.6E, right). When 
assessed by SDS-PAGE (Figure 4.6E, left), the protein absorption for PCSN(R) was enhanced five-
fold compared with that for PCSN, indicating that the randomly orientated conjugation of GST-
HER2-Afb may change surface properties and increase protein–nanoparticle interactions. Next, the 
succinic anhydride-modified PCSN [PCSN(−)] were prepared to generate additional carboxylate 
groups on GST-HER2-Afb, which has a negatively charged function but still binds on GSH-MSN in 
the same orientation as GST-HER2-Afb (Figure 4.6E, middle). The SDS-PAGE analysis confirmed 
that the protein absorption observed for PCSN(−) was similar to that of PCSN, implying that once 
thermodynamically favorably orientated on nanoparticles, the supramolecularly adsorbed proteins can 
stabilize the colloid and significantly reduce the interactions with external serum proteins. We further 
employed coarse-grained molecular dynamics method to observe the interactions between coated 
silica nanoparticles (i.e. PEG-MSN, PCSN(R), PCSN (−), and PCSN) and serum protein (i.e. albumin) 
in the vicinity of their interface at the molecular level (simulation method details in the Figure 4.8-10), 
which suggests that the orientation of GST-HER2-Afb attached to the surface of silica nanoparticles 
as well as the electrostatic interactions can be an important factor. 
We studied the cellular uptake of PCSN by macrophages, one of the most important components of 
the immune defense system, which act by clearing foreign molecules from the blood. Being able to 
evade internalization by phagocytic cells would provide a drug carrier that can accomplish long-term 
blood circulation and enhanced arrival at the target tumor22, 38. PCSNs or PEG-MSNs loaded with a 
fluorescent dye, DiI, were pretreated with 55% FBS for 1 h at 37 °C and then incubated with a murine 
macrophage-like cell line, RAW264.7, for 6 h in culture medium supplemented with 10% serum 
(Figure 4.11A). Confocal microscopy imaging revealed that the internalization of the DiI-loaded 
PEG-MSN was significant, but was rarely observed for the DiI-loaded PCSN (Figure 4.11B), which 
was further confirmed by flow cytometry (Figure 4.11C). Cell viability analysis also confirmed 
reduced cellular uptake of PCSN when the camptothecin-loaded PCSN was applied (Figure 4.11D). 
These results indicate that PCS on PCSN significantly reduced internalization into macrophages. A 
recent study reported that the biomolecular corona formation with a specific composition provides a 
stealth effect on the macrophage recognition39. Similarly, our results suggest that the scarce corona 
formation on PCSN caused by the supramolecularly pre-coated proteins could confer stealth 
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properties to evade immune cells and subsequent elimination by the MPS. Next, to investigate the 
cell-specific targeting ability of PCSN, the HER2-receptor-overexpressing cancer cell line SK-BR3 
and the HER2-receptor-negative cell line HEK293T were treated with Dil- or camptothecin-loaded 
PCSN after pre-incubation in 55% FBS for 4 h (Figure 4.11E). The significant uptake of Dil-loaded 
PCSN by SK-BR3 cells rather than HEK293T cells, mediated by receptor-mediated endocytosis 
(especially macropinocytosis), was confirmed by confocal fluorescence microscopy (Figure 4.11F and 
Figure 4.12A) and FACS (Figure 4.12B). The targeted internalization was further confirmed by 
measuring cellular viability for the camptothecin-loaded PCSN, which exhibited dose-dependent 
toxicity on SK-BR3, while exhibiting lower toxicity on HEK293T (Figure 4.11G). A control, HER2-
binding affibody (Afb) modified MSNs (Afb-MSN) was also evaluated and it confirmed that GST 
plays an important role in reducing interactions among the serum proteins as well as supramolecularly 
conjugating on particle (Figure 4.13). To examine the versatile targeting platform for PCS, EGFR-
binding Afb combined with glutathione-S-transferase (GST-EGFR-Afb) was also applied on GSH-
MSN and its targeting ability to MDA-MB468 cells (EGFR-positive cancer cells) was confirmed 
(Figure 4.14). Taken together, these results show that PCSN exhibited cell-specific targeting ability as 
well as stealth properties.                                         
To translate the outcomes of PCSN in an in vivo tumor model, nanoparticles loaded with the far-red 
fluorescent dye DiD were systemically injected via the tail vein into nude mice (n = 6 mice per group) 
bearing SK-BR3 cell xenografts, after which the tumor accumulation of PCSN was monitored. 
Considering the lowest accumulation efficacy of GSH-MSN observed from initial experiments 
(Figure 4.15A), our studies focused on the comparison between PCSN and PEG-MSN. The in vivo 
live imaging results showed the presence of 1.8-fold enhanced fluorescent signals in tumor sites from 
the PCSN-treated group compared with the PEG-MSN-treated group at 0.5 h after injection (Figure 
4.15B), which was maintained until 24 h, while the fluorescent signals for PEG-MSN gradually 
decreased with time at 8 h (Figure 4.15C). The biodistribution of nanoparticles was then assessed by 
measuring the fluorescence of DiD in harvested organs and tumors upon necropsy 48 h after injection. 
The fluorescent signals of tumors from the PCSN group were enhanced 2.5-fold in comparison with 
those of the PEG-MSN group (Figure 4.16A). Moreover, the fluorescent intensity in the tumor for the 
PCSN group was seven-fold higher than that in reticuloendothelial organs (e.g., liver and spleen), 
whereas no significant difference in fluorescent intensities between tumors and the reticuloendothelial 
organs was observed for the PEG-MSN groups (Figure 4.16B), indicating that PCS enabled the 
nanoparticles to evade the immune system and undergo enhanced accumulation in the target tumor. In 
vivo antitumor efficacy was further evaluated by intravenously administering camptothecin-loaded 
PCSN (PCSN(CPT)), PEG-MSN (PEG-MSN(CPT)), PCSN, camptothecin (Free-CPT), and 
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phosphate-buffered saline (PBS) to the SK-BR3 tumor-bearing mice. Compared with the PEG-
MSN(CPT)-treated group, the PCSN(CPT)-treated group exhibited higher therapeutic efficacy, 
resulting in ~90.0% inhibition of tumor growth in terms of volume and 2.5-fold enhancement of 
inhibitory effects (Figure 4.16C). Subsequently, by examining tumor weight reduction and 
histopathology after necropsy on day 22, the PCSN(CPT)-treated group was shown to have enhanced 
therapeutic efficacy for tumor growth inhibition (Figure 4.15D). Additionally, hematoxylin and eosin 
(H&E)-stained lung, liver, spleen, and kidney samples showed no apparent abnormalities or lesions at 
day 21 after camptothecin-loaded PCSN treatment (Figure 4.17). These results indicate that PCSN 
increases the tumor targeting ability, enhancing the efficacy of cancer chemotherapy. Collectively, we 
found that the supramolecular binding of GST-HER2-Afb on particles enabled the maintenance of 
conformational stability and further minimized interactions with serum proteins. In vitro and in vivo 
experiments confirmed that PCSN improved the targeting ability and therapeutic efficacy. These 
findings indicate that exploiting protein coronas can provide a tool for a targeting platform. 
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Figure 4.1 Protein corona shield nanoparticles(PCSN) (A) Mass spectrometry analysis of the GST-
HER2-Afb showed a mass of 36.3 kDa. (B) Zeta-potential analysis of mesoporous silica nanoparticle 
(MSN) (−23 mV), GSH-MSN (−39 mV), GST-HER2-Afb (−5.25 mV), and PCSN 
(−5.3 mV). (C) Size distribution plots of PCSN. (D) Images of cellular uptake of fluorescein 5 
maleimide-modified GST-HER2-Afb by the target cell (SK-BR3) and the negative control (MCF-
10A). (E) Transmission electron microscopic images of GSH-MSN and PCSN (scale bar represents 
100 nm). All bar graphs were reported as means ± standard deviations (SDs) for three experimental 
replicates (n = 3) 
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Figure 4.2 Preparation of GST-HER2-Afb. (A) Purified GST-HER2-Afb identification by SDS-
PAGE. (B) Quartz crystal microbalance (QCM) analysis of HER2- Afb and GST-HER2-Afb. (C) Cell 
cytotoxicity test of GST-HER2-Afb in SK-BR3 and MCF-10A cells. All bar graphs were reported as 
means ± standard deviations (SDs) for three experimental replicates (n =3). 
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Figure 4.3 Preparation of GSH-MSN. (A) Scheme of GSH-modified mesoporous silica nanoparticles 
(GSH-MSNs). (B, C) Pore size and surface area change from MSNs to GSH-MSNs. (D) FTIR 
analysis for MSNs and GSH-MSNs. 
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Figure 4.4 Cargo loading analysis of GSH-MSNs. UV-VIS absorption of the supernatant of (A) DiI, 
(B) DiD, (C) CPT, and (D) DOX solutions. 
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Figure 4.5 Protein absorption and size difference analysis for PCSNs.(A) Hydrodynamics diameter 
change between GSH-MSNs and PCSNs. (B) Concentration curve for BSA on GSH-MSNs 
determined using the BCA assay. The absorbance of the sample is 0.148, and the concentration is 0.27 
mg/mL. 
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Figure 4.6 Proteomic study of surface protein corona. (A) GSH-MSN, PEG-MSN, and PCSN were 
treated with 55% serum for 1, 2, and 4 h, and the amount of serum protein attached to the surface was 
determined by SDS-PAGE. (B) Band intensity difference. (C) Classification of protein corona 
components characterized by quantitative LC-MS/MS. A total of 183 proteins were identified and the 
78 most abundant proteins were used to make the heat map. (D) Proteins attached to each particle 
were classified by weight (kDa), category, and pI. (E) GSH-MSN, PCSN(R), PCSN(−), and PCSN 
were treated with 55% serum for 1 h and the amount of serum protein attached to the surface was 
determined by SDS-PAGE. All bar graphs were reported as means ± standard deviations (SDs) for 
three experimental replicates (n = 3) 
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Figure 4.7 The physical-characterizations of nanoparticle-serum protein interaction. Size, surface 
charge and PDI analysis of (A) GSH-MSN (B) PEG-MSN (C) PCSN with treatment of the 55% 
serum for 1h, 2h and 4h. 
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Figure 4.8 Coarse-grained molecular models. (A) Coarse-grained model of albumin. Negatively 
charged side chains in GLU and ASP are shown with yellow beads and coarse-grained schemes are 
presented. Coarse-grained models of (B) GST-HER2 Afb and (C) charge-modified GST-HER2 Afb. 
Yellow, blue and black dotted boxes showed magnified coarse-grained mapping of linking site 
between GST and Afb, GSH and modified side chain in GST, respectively. Positively charged side 
chains in HIS, LYS and ARG are shown in blue. (D) Coarse-grained model of PEG-PDS polymer. 
Red, blue and black dotted boxes represent PEG chain, DTT-treated chain and pyridothione-treated 
chain, respectively. Martini bead types for GSH, modified side chain and PEG-PDS polymer were 
shown with magnification. 
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Figure 4.9 Simulations of surface protein corona phenomenon. (A) Final configurations of CGMD 
simulation of PEG-MSN and PCSN series interacted with albumin in water environment. Water is 
omitted for clear view. Blue and red dotted boxes show the structures of bead models and binding 
states, respectively. Color scheme is presented in detail (Supplementary Fig. 7) (B) Radial distribution 
functions of constituents of PEG-PDS with albumin in PEG-MSN and residues of GST with albumin 
in PCSN(R), respectively. 
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Figure 4.10 Adsorption of GST-HER2 Afb proteins on silica surface. Initial and final configurations 
of adsorption simulation with GST-HER2 Afb proteins on silica surface. The red-and blue-highlighted 
proteins represent models with adsorption directions set to Afb and GST, respectively. 
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Figure 4.11 In vitro experiment and stealth effect of PCSN. (A) Schematic showing the avoidance of 
phagocytosis by a macrophage. (B) Confocal microscopy images of DiI-loaded PCSN and PEG-MSN, 
and free DiI incubated for 6 h in RAW264.7 cells (scale bar is 20 μm). (C) FACS analysis of PCSN 
and PEG-MSN incubated in RAW264.7 cells for 6 h. (D) Cell cytotoxicity assay of PCSN and free 
camptothecin (CPT) on RAW264.7 cells (48 h of incubation). (E) Schematic of the targeting ability of 
PCSN treated with 55% serum. Cellular uptake confocal microscopy images of (F) DiI-loaded PCSN 
to HEK293T cells (negative control) and to SK-BR3 (target cells). (G) Cellular uptake confocal 
microscopic images of camptothecin-loaded PCSN to SK-BR3 and cell cytotoxicity assay (scale bar is 
10 μm). All bar graphs were reported as means ± standard deviations (SDs) for three experimental 
replicates (n = 3) 
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Figure 4.12 Pathway test of PCSN (A) Cellular uptake image of PCSN to SK-BR3 in the presence of 
amiloride, sucrose , MβCD . (B) fluorescence-activated cell sorting analysis of dye (DiI)-loaded 
PCSN (scale bar is 5 μm). 
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Figure 4.13 In-vitro experiment for randomly modified MSN. Cellular uptake experiment for dye-
containing (DiIC18) HER2-binding affibody (Afb) modified MSNs (Afb-MSN) on SK-BR3 cell. The 
Afb-MSN was pre-treated in (A) 10% serum and (B) 55% serum for 1 hour (Scale bar is 20 μm and 
scale bar of inset image is 5 μm). 
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Figure 4.14 Preparations of GST-EGFR-Afb and EGFR-PCSNs. (A) Mass spectrometry analysis of 
the GST-EGFR-Afb was 36.1 kDa; (B) cell cytotoxicity test of GST-EGFR-Afb in MDA-MB468 and 
MCF-10A cells; (C) cellular uptake images of fluorescein 5 maleimide-modified GST-EGFR-Afb 
(GST-EGFR-Afb F5M) into the target cell (MDA-MB468) and the negative control (MCF-10A) 
(Scale bar is 20 μm); (D) CPTloaded EGFR-PCSNs into MDA-MB468 (scale bar is 5 μm) and 
HeK293T cells (scale bar is 10 μm); (E) cell cytotoxicity assay; (F) fluorescence-activated cell sorting 
analysis of dye (DiI)-loaded EGFR-PCSNs. Figure B and E graphs were reported as means ± standard 
deviations (SDs) for three experimental replicates (n =3). 
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Figure 4.15 Pre-in vivo and -ex vivo experiments with PCSNs. (A) Ex vivo fluorescence imaging 
data of each organ; (B) changes in DiD intensity of tumors in each group per each time (each animal 
received a particle dose of 1 mg/mice (~50 mg/kg), which delivers ~3 mg/kg of DiD per mouse, n = 
3/group by IV injection), (Scale bar is 2 cm); (C) representative whole-body fluorescence images of 
subcutaneous SK-BR3 tumor-bearing mice intravenously injected with nanoparticles (1.5 mg/kg of 
DiD per mouse, n = 6/group by IV injection); (D) tumor weight of each group (n = 6/group, mean ± 
SD, statistical significance was calculated by one-way analysis of variance. *P < 0.05, **P < 0.01, 
*** P < 0.001). All bar graphs were reported as means ± standard deviations (SDs) (n = 6/group). 
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Figure 4.16 Ex vivo and in vivo efficiency of PCSN. (A, B) Fluorescence images of organs and 
tumors 48 h after intravenous injection and biodistribution of injected formulations in animals with 
SK-BR3 tumor xenograft from fluorescence intensity analysis. In vivo antitumor effects in different 
treatment groups loaded with camptothecin (CPT) (1.5 mg/kg of mice) (scale bar is 2 cm). (C) Growth 
curve of tumor volume after intravenous injection with various groups of carriers until day 21 (n = 6 
mice per group, mean ± 1 day [n = 6 mice per group, mean ± SD, statistical significance was 
calculated by one-way analysis of variance, *P < 0.05, **P < 0.01] 
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Figure 4.17 Histological evaluations of tumor tissues. Hematoxylin and eosin (H&E) staining of the 
lung, liver, spleen, kidney, and tumor. (Scale bar is 50 μm) 
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4.4 Conclusions 
 
Targeted drug delivery using nanoparticles can minimize the side effects of conventional 
pharmaceutical agents and enhance their efficacy. However, translating nanoparticle-based agents into 
clinical applications still remains a challenge due to the difficulty in regulating interactions on the 
interfaces between nanoparticles and biological systems. Here, we present a targeting strategy for 
nanoparticles incorporated with a supramolecularly pre-coated recombinant fusion protein in which 
HER2-binding affibody combines with glutathione-S-transferase. Once thermodynamically stabilized 
in preferred orientations on the nanoparticles, the adsorbed fusion proteins as a corona minimize 
interactions with serum proteins to prevent the clearance of nanoparticles by macrophages, while 
ensuring systematic targeting functions in vitro and in vivo. This study provides insight into the use of 
the supramolecularly built protein corona shield as a targeting agent through regulating the interfaces 
between nanoparticles and biological systems. 
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Conclusions 
 
 
In this dissertation, I developed protein nanoparticle-based cargo-delivery system. Conventional 
drugs have many limitations on their use due to their physicochemical properties including low 
solubility, stability, short half-life, and high diffusion rate to normal tissues. Here, I proved that 
protein nanoparticle could be utilized in cargo delivery for enhanced efficacy of drugs and low side-
effects of cargoes. In addition, targeting ligands including antibodies and affibody molecules were 
decorated on nanoparticles for active targeting as well as passive targeting via EPR effect. 
 
In chapter 2, I developed a universal multivalent antibody-binding nanoplatform by insertion of ABDs 
to AaLS protein cage nanoparticle. ABD–AaLS effectively captures various types of antibodies derived 
from diverse species on demand, and that their complexes selectively recognize and bind to their target 
cells in vitro, guided by antibodies displayed on the surface of ABD–AaLS. 
 
In chapter 3, I developed target‐tunable P22 VLP‐based polyvalent delivery nanoplatforms, ligated 
two different targeting affibody molecules on demand. Here, I utilized bacterial superglue 
SpyTag/SpyCathcer forming covalent isopeptide bond. P22 VLP having two different affibody 
molecules could load pH‐sensitive prodrugs and selectively kill target cells in vitro. 
 
In chapter 4, I developed cloaking nanoparticles for drug delivery. I bound GST fused affibody 
molecules on GSH expressing mesoporous silica nanoparticles via non-covalent binding of GST/GSH. 
Bound fusion protein stabilized in preferred orientations on the nanoparticles, which minimize 
interactions with serum proteins to prevent the clearance of nanoparticles by macrophages, while 
ensuring systematic targeting functions in vitro and in vivo 
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